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Innate Immune Response to a Saponin Adjuvant in the Pig. 
Application of Gene Expression Profiling 
Abstract 
Vaccination is one of the most powerful ways to prevent infectious diseases. Successful 
vaccines produce a long-term immunity including effector T and B lymphocytes. In this 
context, adjuvants have a key role in vaccines by stimulating the innate immunity and 
thereby enhancing and shaping the subsequent adaptive immune response. The aim of 
this thesis was to elucidate the early innate immune response to the saponin-based 
adjuvant Matrix-M in the pig. Gene expression profiling was applied to monitor the 
global transcriptional response to Matrix-M in vivo. The innate immune response was 
further characterized by quantitative PCR analysis in vivo and in vitro and the early 
immunomodulatory effect of Matrix-M was evaluated in a contact exposure model. A 
mild inflammation and a cellular influx were recorded at the injection site and in the 
draining lymph node 24 hours after intramuscular injection of Matrix-M in pigs. In 
accordance, microarray analysis detected transcriptional alterations of genes for 
cytokines, chemokines and pattern recognition receptors in both tissues. Interferon-
regulated genes were significantly overrepresented in these tissues, accompanied by 
increased gene expression for interferon-β in in the draining lymph node and 
interferon-α in blood. Transcriptional responses to Matrix-M in vitro were generally 
low but increased culture and exposure time affected genes for pro-inflammatory 
cytokines and TH cytokines in lymphocytes. Low levels of interferon-α gene expression 
were also detected in monocyte-derived dendritic cells. A contact exposure model was 
established to mimic field conditions when allocating grower pigs, by mixing pigs of 
various health statuses. After transport and mixing with conventionally reared pigs, all 
specific pathogen free (SPF) pigs in this model developed respiratory disease. Systemic 
symptoms that correlated with granulocyte counts, serum amyloid A levels and 
transcription of IL18 and TLR2 were provoked in two out of four SPF pigs that received 
saline prior to exposure, but not in those given Matrix-M. Taken together, the 
application of gene expression profiling successfully identified the induction of innate 
immune responses in porcine tissues and indicated that Matrix-M primes the host for 
further immune regulation. Thus, Matrix-M or similar saponin formulations are 
potentially useful clinical immunomodulators or adjuvants in emergency vaccines. 
Keywords: porcine, adjuvant, ISCOM-Matrix, Matrix-M, microarray, qPCR, interferon, 
infection model. 
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1 Background 
Vaccines have traditionally been constructed with the aim to defend the host 
against a pathogen by creating a protective and long-lasting immunity. Later, 
also therapeutic vaccines have been developed in order to re-direct or dampen 
immune responses, for example at allergic or autoimmune reactions, or to 
evoke and enhance immune reactions in immune-compromised individuals. 
For all these purposes it is necessary to understand how the immune reactivity 
can be modulated in a desired direction. Adjuvants have been defined as 
“components capable of enhancing and/or shaping antigen-specific immune 
responses” (Reed et al., 2013) and is an important component in most vaccines. 
The word adjuvant is adapted from the Latin word adjuvare, meaning “to 
help”. Their effects in combination with various antigen preparations have 
been scrutinized in several species, but effects of adjuvant components in the 
absence of antigen are less studied. 
Saponins from the soapbark tree Quillaja saponaria Molina are effective 
adjuvants with immunomodulatory capacities. Purified fractions of such 
saponins in combination with cholesterol and phospholipids create nanoparticle 
adjuvant formulations known as ISCOM-Matrix or Matrix (Lovgren & Morein, 
1988). Matrix formulations have successfully been used in a number of 
vaccines, but their mechanism of action in the absence of antigen is not fully 
understood. In the present thesis, transcriptomic methods were applied to 
elucidate early innate immune responses to a Matrix formulation in the pig. 
There is need for new and improved vaccines for pigs and the pig is an 
increasingly interesting model for human vaccine development (Dawson et al., 
2016; Fairbairn et al., 2011). 
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1.1 Vaccine adjuvants 
According to the “danger model”, immune responses to antigen are elicited by 
danger molecules mainly detected by germ-line encoded pattern recognition 
receptors (PRRs; Matzinger, 2002). Danger signals can be derived from the 
host, as endogenous damage-associated molecular patterns (DAMPs; also 
called alarmins) or from pathogens, in the form of exogenous pathogen-
associated molecular patterns (PAMPs). Triggering the innate immunity leads 
to production of cytokines that activate and modulate the ensuing adaptive 
immune responses to foreign antigens presented in that context.  
Vaccines based on live, killed or attenuated microorganisms naturally 
contain PAMPs that activate the immune system, whereas purified proteins in 
subunit vaccines often have poor immunogenicity (Lövgren-Bengtsson et al., 
2016; Quinn et al., 2013; Reed et al., 2013). Most subunit vaccines thus need 
to be formulated with adjuvants in order to evoke long-lasting immune 
responses. Potent adjuvants are antigen sparing, reduce the need for booster 
doses and induce functional and cross-protective antibodies as well as cell-
mediated immunity (Lee & Nguyen, 2015). Adjuvants exert these effects by 
promoting production and release of cytokines and chemokines that recruit 
immune cells to the local tissue, by antigen targeting to antigen-presenting 
cells that are activated and maturated and possibly also by facilitating antigen 
presentation (Awate et al., 2013). Immune responses against vaccine antigens 
are typically divided into T helper (TH) 1 types, effective against intracellular 
pathogens, and TH2 types, effective against extracellular pathogens. 
Adjuvants have been divided into three broad categories: 
immunomodulatory molecules, particulate formulations, and combinations of 
the two (Reed et al., 2013; Cox & Coulter, 1997), as outlined in Table 1. 
Synthetically derived PAMP analogues, referred to as immunomodulatory 
molecules activate the innate immunity by triggering PRRs. Particulate 
formulations adsorb antigen and are thought to function as delivery systems to 
antigen-presenting cells (Reed et al., 2013; Cox & Coulter, 1997), but 
convincing evidences for this concept still remains to be attained (Awate et al., 
2013). Several particulate adjuvants are however known to activate innate 
immune responses in an immunomodulatory manner, by up-regulation of 
cytokine genes and recruitment and maturation of immune cells (Caproni et al., 
2012; Mosca et al., 2008; Seubert et al., 2008). 
The particulate formulation of aluminium salts, referred to as alum, has 
been the most widely used adjuvant in human vaccines since its discovery in 
the 1920s (reviewed in Marrack et al., 2009). Alum enhances antibody 
production and induces TH2 type immune responses, but gives no cytotoxic T 
lymphocytes (CTLs). Alum promotes immune responses in the absence of toll-
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like receptor (TLR) signalling (Gavin et al., 2006), but the NLR family pyrin 
domain containing 3 (NLRP3) inflammasome may be necessary for its 
adjuvant effect (Marrack et al., 2009; Eisenbarth et al., 2008). Similar to alum, 
all currently licenced adjuvants for human use are particulate formulations, or 
combined with one (Table 1). MF59 is a squalene oil-in-water emulsion used 
in influenza vaccines. It was originally described as a TH2 adjuvant (Valensi et 
al., 1994) although later studies suggest a more balanced TH1/TH2 response 
(Seubert et al., 2008). The AS04 adjuvant has a non-toxic lipopolysaccharide-
analogue combined with alum, which completely shifts the immune response 
from TH2 to TH1 (Didierlaurent et al., 2009). Virus-like particles consist of 
virus envelope proteins without any genomic material, presenting antigen in a 
multimeric form that increase the immunogenicity (Morein et al., 1978). Virus-
like particles are taken up by antigen-presenting cells and the antigens are 
presented on both major histocompatibility complex (MHC) I and MHC II 
molecules (Kushnir et al., 2012). 
Based on the concept that engagement of PRRs activates the innate 
immunity, a number of specific PRR agonists have been evaluated as 
adjuvants, including the TLR agonists Pam3CSK4 (TLR2), 
polyinosinic:polycytidylic acid (poly I:C; TLR3), monophosphoryl lipid A 
(TLR4), flagellin (TLR5), imiquimod/resiquimod (TLR7/8) and CpG (TLR9). 
However, none of these have been licenced for human use (Table 1). Many of 
these molecules target receptor pathways for intracellular pathogen sensing, 
inducing type I interferons (IFNs) that can promote the induction of CTLs (Le 
Bon et al., 2003). Another group of immunomodulatory substances is the 
saponins, which can also be formulated as a particulate adjuvant under certain 
conditions (Lovgren & Morein, 1988). 
1.2 Saponin-based adjuvants 
Adjuvant active saponins, particularly those extracted from Quillaja saponaria 
Molina, Quil-A. are potent immune modulators that have been used in animal 
vaccines for decades (Sun et al., 2009). Traditional use of Quil-A in animal 
vaccines is in aqueous solutions but there are other formulations developed for 
increased activity or stability. Quil-A saponins have an inherent toxicity that 
springs from its affinity to cholesterol, thereby disrupting cell membranes and 
provoking subsequent lysis (Kensil et al., 1991). A more recent development 
for use in human vaccines is the selected specific saponin compound QS21 
(Kensil & Kammer, 1998). QS21 vaccines still have some tolerability issues 
and current clinical trials for QS21 are mainly intended for therapeutic 
vaccines (Bigaeva et al., 2016), where tolerability is of less concern. 
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Table 1. Classification of selected adjuvants  
Adjuvant Type of adjuvant Type of immune 
response 
Clinical 
statusa 
Immunomodulatory molecules   
Pam3CSK4 TLR2 ligand TH1, TH2, CTL Preclinical 
Poly I:C TLR3 ligand TH1, CTL Phase 2 
MPL (LPS analogue) TLR4 ligand TH1 Phase 3 
Flagellin TLR5 ligand TH1, TH2 Phase 2 
Imiquimod TLR7 ligand TH1, CTL Phase 3 
Resiquimod TLR7/8 ligand TH1, CTL Phase 2 
CpG TLR9 ligand TH1, CTL Phase 3 
TDB CLR ligand (Mincle) TH1, TH17 Phase 1 
QS21 Saponin TH1, TH2, CTL Phase 3 
    
Particulate formulations    
Alum Mineral salt TH2 Licenced 
MF59 Oil-in-water emulsion TH1, TH2 Licenced 
AS03 Oil-in-water emulsion + 
α-tocopherol 
TH1, TH2b Licenced 
Liposomes Antigen delivery formulation TH1, TH2, CTL Preclinical 
Virus-like particles Antigen delivery formulation TH1, TH2, CTL Licensedc 
    
Combined formulations    
AS01 MPL + QS21 + liposome TH1, CTL Phase 3 
AS02 MPL + QS21 + AS03 emulsion TH1 Phase 3 
AS04 MPL + Alum TH1 Licenced 
GLA-SE TLR4 ligand + emulsion TH1 Phase 1 
ISCOM-Matrix Matrix-formulated saponin TH1, TH2, CTL Phase 2 
Modified after Reed et al. (2013), Awate et al. (2013), Lee and Nguyen (2015), Temizoz et al. (2016) and 
Apostolico et al. (2016). CpG, cytidine-phosphate-guanosine oligodeoxynucleotides;	   CLR,	   C-­‐type	   lectin	  
receptor;	   CTL,	   cytotoxic	   T	   cell	   responses;	   GLA-­‐SE,	   glucopyranosyl	   lipid	   A	   stable	   emulsion;	   LPS,	  
lipopolysaccharide;	  MPL,	  monophosphoryl	   lipid	   A;	   Pam3CSK4,	   tri-­‐palmitoyl-­‐S-­‐glyceryl	   cysteine	   SK4;	   Poly	   I:C,	  
polyinosinic-­‐polycytidylic	  acid;	  TDB,	  trehalose-­‐6,6-­‐dibehenate;	  TH,	  T	  helper;	  TLR,	  toll-­‐like	  receptor.	  
a Status on clinical trials for human vaccines; b (Morel et al., 2011); c (Kushnir et al., 2012) 
Purified fractions of Quil-A saponin are also used for formulation of 
immunostimulating complexes (ISCOMs.) The strong affinity between saponin 
and cholesterol is utilised to form the core matrix of the ISCOM, whereas 
phospholipids are needed for the inclusion of antigens (Lovgren & Morein, 
1988). Binding of saponin to cholesterol also reduces the haemolytic and 
cytotoxic effects of the saponins. 
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1.2.1 ISCOM and Matrix formulations 
The ISCOM is a cage-like 40 nm particle made from antigen, cholesterol, 
phospholipids and Quil-A (Morein et al., 1984). It was formulated in an effort 
to combine the adjuvant activity of saponin in an immunogenic multimeric 
particle. The ISCOM generates superior antibody levels compared to antigen-
containing micelles (Morein et al., 1984). On top of improved antibody 
production, ISCOMs can induce MHC class I-restricted CTLs (Takahashi et 
al., 1990). The immune response elicited by ISCOMs was protective at 
challenge with influenza virus in mice, both after mucosal and parenteral 
delivery (Lövgren et al., 1990). In line with induction of CTLs, ISCOMs 
induce an immune response with both TH1 and TH2 cytokines (Sjolander et al., 
1997). 
The original ISCOM formulation however suffered from some technical 
limitations. Not all types of antigen can be included in the ISCOM, the process 
of incorporating antigen is rather complex and the fixed antigen:saponin ratio 
is not always optimal as the amount of saponin needed for the ISCOM 
structure is often higher than what is needed for the adjuvant effect (Lövgren 
Bengtsson et al., 2011). However, ISCOMs without incorporated antigen, so-
called ISCOM-Matrix or Matrix, work as an adjuvant when simply mixed with 
antigens. Matrix formulated with Quil-A saponins and cholesterol only, i.e. 
even without phospholipids, could increase the spontaneous proliferation of 
spleen cells collected from injected mice (Fossum et al., 1990). Matrix added 
to influenza virus micelles significantly increased antibody responses in 
vaccinated mice (Rönnberg et al., 1995) and Matrix mixed with influenza virus 
micelles elicited immune responses in mice with similar amplitude and 
characteristics as influenza virus ISCOMs did (Lövgren-Bengtsson & 
Sjolander, 1996). Matrix particles can also be formulated with fractions of 
Quil-A, designated QH-A, QH-B and QH-C (Rönnberg et al., 1995). Studies 
on QH-A and QH-C when included in ovalbumin ISCOMs indicated that 
QH-C is a more potent inducer of antibodies, whereas antigen-specific IFN-γ 
production is mainly dependent on QH-A (Johansson & Lövgren Bengtsson, 
1999). 
Matrix formulations based on purified saponin fractions have been 
commercialized as standalone adjuvants. ISCOMATRIX by CSL Ltd. is 
created from a mix of QH-A and QH-C at a 7:3 ratio (Morelli et al., 2012). 
Isconova AB, acquired by Novavax Inc. in 2013, developed the formulations 
Matrix-Q from Quil-A and Matrix-M from a combination of Matrix-A and 
Matrix-C (formulations of QH-A and QH-C). By mixing the separately formed 
Matrix particles into Matrix-M, the dose of the more reactogenic Matrix-C can 
be reduced while maintaining the adjuvant effect (Lövgren Bengtsson et al., 
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2011). Matrix-M and Matrix-Q were previously available as adjuvants for 
research purposes under the trade names AbISCO-100 and AbISCO-300, 
respectively. 
1.2.2 Matrix-formulated saponin in vaccines 
Similar to ISCOMs, antigen simply mixed with ISCOMATRIX induces strong 
antibody responses and CTLs (reviewed in Morelli et al., 2012). In accordance, 
Matrix-M vaccines induce TH1- and TH2-related long-lasting antibody 
responses in mice and humans (Pedersen et al., 2014; Magnusson et al., 2013; 
Madhun et al., 2009) and CTLs in mice (Quinn et al., 2013). Multifunctional 
TH1 CD4+ cells producing interleukin (IL)-2, IL-12 and IFN-γ, typically 
considered to correlate with protection, are also induced by Matrix-M vaccines 
(Madhun et al., 2009). Furthermore, both Matrix-M and ISCOMATRIX have 
an antigen dose-sparing effect in vaccines (Lövgren Bengtsson et al., 2011; 
Maraskovsky et al., 2009). Matrix-C was shown to promote immunity also in 
the presence of maternal antibodies (Heldens et al., 2009). Matrix-C is used in 
a commercial horse influenza vaccine since 2006 (Equilis Prequenza Te; MSD 
Animal Health). Human clinical trials are currently ongoing for both 
Matrix-M1 and ISCOMATRIX vaccines2. 
Matrix-M and ISCOMATRIX have been used together with TLR ligands in 
experimental vaccines. Matrix-M in combination with poly I:C increased the 
number of multifunctional CD4+ T cells, and increased survival in 
experimental challenge to Listeria monocytogenes and vaccinia virus in mice 
(Quinn et al., 2013). A vaccine adjuvanted with ISCOMATRIX in combination 
with both poly I:C and CpG was used therapeutically with some success 
against established tumours in a mouse melanoma model (Silva et al., 2015). 
However, in a study on non-human primates, addition of CpG to a vaccine 
adjuvanted with Matrix-M did not enhance the antibody production, memory 
B-cell formation or the antigen specific CD4+ response, speculatively due to 
sufficient TH1 activation by Matrix-M alone (Martinez et al., 2015). 
The induction of CTLs by ISCOM-based vaccines is intriguing. In a study 
with Matrix-M, its ability to induce CTLs was similar to that of poly I:C, a 
strongly TH1-prone adjuvant (Quinn et al., 2013). Induction of CTLs facilitated 
by ISCOMATRIX was required for the therapeutic effect against experimental 
melanoma in mice (Silva et al., 2015). Antigen-specific CTLs requires MHC 
class I presentation, which in turn typically requires the antigen to be present in 
the cytosol as an intracellular pathogen or by means of cross-presentation by 
antigen-presenting cells. ISCOMATRIX can induce such cross-presentation in 
                                                        
1. http://novavax.com/page/11/clinical-stage-pipeline/ 
2. http://www.cslbehring.com/research-development/core-capabilities.htm/ 
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conventional dendritic cells (DCs) by translocation of ingested antigen from 
the endosome/lysosome to the cytosol (Duewell et al., 2011; Schnurr et al., 
2009). Maraskovsky et al. (2009) argue that this is not due to passive 
membrane disruption caused by saponins associating with cholesterol in cell 
membranes, as lysosomal acidification was required for the cytosolic 
translocation (Schnurr et al., 2009). Furthermore, break of endosomal integrity 
correlated with inflammasome activation and pyroptosis in macrophages 
treated in vitro with ISCOMATRIX (Wilson et al., 2014). 
1.2.3 Cell migration and recruitment by Matrix-formulated saponin 
Sheep lymph node cannulation experiments by Windon et al. (2000) showed 
that the total cell output from the local lymph node decreased immediately 
following injection with ISCOMATRIX. This phenomenon is referred to as 
“node shutdown” and is associated with an active immune response. The node 
shutdown remained for up to 48 hours, after which the output increased above 
baseline until six days after administration (Windon et al., 2000). In the same 
study, neutrophils were recorded in the lymph after ISCOMATRIX 
administration. Rapid neutrophil infiltration after intraperitoneal injection in 
mice was described earlier also for ISCOMs containing influenza virus 
antigens (Watson et al., 1989). In mice, neutrophils was the most increased cell 
type in both draining lymph node and spleen 48 hours after subcutaneous 
injection with Matrix-M (Reimer et al., 2012). Also, the numbers of T and B 
cells, DCs (CD11c+) and macrophages (F4/80int) were increased in the draining 
lymph node and, to some extent, in the spleen. Dendritic cells showed 
increased expression of the co-stimulatory molecule CD86, indicating 
activation and maturation (Reimer et al., 2012). Similar results were presented 
for ISCOMATRIX in mice, for which cell recruitment into the draining lymph 
node started already after 6 hours, and reached maximum 24 hours after 
administration (Wilson et al., 2012; Duewell et al., 2011). ISCOMATRIX 
administration in mice, using a subcutaneous air-pouch technique, also led to 
recruitment of neutrophils and monocytes to the administration site within 4 
and 16 hours, respectively (Wilson et al., 2012). The pronounced increases in 
cell recruitment and migration to the draining lymph node described above 
were not detected for alum, Freund’s complete adjuvant or the squalene-based 
adjuvant AS03, in a comparative study with Matrix-M conducted in mice 
(Magnusson et al., 2013). In contrast, Calabro et al. (2011) reported rapid 
recruitment of both neutrophils and monocytes to the injection site and 
draining lymph node after intramuscular injection both with alum and MF59. 
Neutrophils could not be detected in sheep after injection with soluble forms of 
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the saponins QH-A and QH-C (Windon et al., 2000), suggesting that 
formulating saponins into Matrix is important for neutrophil recruitment. 
1.2.4 Cytokine induction by Matrix-formulated saponin 
Many studies on cytokine production induced by ISCOM-Matrix revolve 
around those produced by antigen-specific cells in recall experiments after 
vaccination. In both humans and mice, such studies show that Matrix-M 
induces TH1 cytokines, such as IL-2 and IFN-γ, together with TH2 cytokines, 
such as IL-4 and IL-10 (Pedersen et al., 2014; Magnusson et al., 2013; Madhun 
et al., 2009). However, these results reflect the adaptive immune responses 
elicited by Matrix-M vaccines rather than the immunostimulatory effect of 
Matrix-M itself. The cytokine response in efferent lymph early after 
stimulation with ISCOMATRIX without antigen was studied in sheep by 
Windon et al. (2000). Within 24 hours the levels of CXCL8, IL-β, IL-6 and 
IFN-γ had increased, in contrast to IL-2 and tumour necrosis factor (TNF)-α. 
In mice, elevated serum levels of IL-6 and CCL4 were detected 48 hours after 
high-dose Matrix-M administration (Reimer et al., 2012). Injection of 
ISCOMATRIX-like ovalbumin ISCOMs increased the levels of IL-1β, IL-5, 
IL-6 and IL-12p40 in the draining lymph node already after 6 hours compared 
to controls injected with phosphate-buffered saline or ovalbumin alone 
(Duewell et al., 2011). 
There are few reports on the direct effect of Matrix on cells in vitro. Wilson 
et al. (2012) noted that exposure of murine bone marrow-derived DCs and 
macrophages to ISCOMATRIX failed to induce any pro-inflammatory 
cytokines and that the bone marrow-derived DCs did not up-regulate any 
activation markers. In murine macrophages, Matrix formed with either Quil-A 
or a mix of QH-A and QH-C dampened the increase in IL-6 and TNF-α 
induced by inactivated respiratory syncytial virus (Hu et al., 2001). However, 
macrophages primed with lipopolysaccharide (LPS) or TNF-α produced large 
amounts of active IL-1β and IL-18 after ISCOMATRIX stimulation in vitro 
(Wilson et al., 2014). This induction was dependent on the NLRP3 
inflammasome. Also Matrix-M and the soluble saponins Quil-A and QS-21 
activate the inflammasome in vitro, after priming with TLR4 agonist (Marty-
Roix et al., 2016; Li et al., 2008). In vivo, IL-18 was required for the 
production of IFN-γ by natural killer cells, induction of CTLs and production 
of TH1 type antibodies by ISCOMATRIX vaccines (Wilson et al., 2014). The 
in vivo IL-18 signalling was dependent on both myeloid differentiation 
primary response gene 88 (MyD88) and DCs, but unexpectedly not on NLRP3. 
Similar to in vivo-results for ISCOMATRIX, antigen-specific responses to a 
 19 
QS-21 based vaccine were not reduced in mice lacking NLRP3 (Marty-Roix et 
al., 2016).  
Thus, there seems to be multiple pathways involved in the adjuvant 
activities caused by Matrix-formulated saponin. Some of the effects were 
shown also for free soluble Quillaja saponins, whereas some effects are 
attributed to the nanoparticle structure of the ISCOM-Matrix. Activation 
through NLRP3 could be detected in vitro after stimulation with Matrix, but 
was not crucial in vivo. In comparison, alum that signals through NLRP3 
(Eisenbarth et al., 2008) only induces TH2-prone immune responses (Marrack 
et al., 2009). Despite some insight into the early mechanisms, it is still open 
questions what processes that are necessary to cause the TH1 responses typical 
for soluble and Matrix-formulated saponins. 
1.2.5 ISCOM-based vaccines in the pig 
Experimental and commercial ISCOM vaccines have been used in a number of 
species, including pigs, horses, cattle, sheep, dogs, cats, seals, chickens, mice 
and non-human primates (reviewed in Morein et al., 2004). In the pig, early 
ISCOM vaccines against pseudorabies (Aujeszky’s disease) demonstrated 
protection at lethal challenge on top of antibody and cellular immune responses 
(Tulman & Garmendia, 1994; Puentes et al., 1993; Tsuda et al., 1991). An 
ISCOM vaccine against Toxoplasma gondii conferred partial protection in pigs 
at challenge (Garcia et al., 2005). Multiple trials have been conducted in 
gnotobiotic pigs with a rotavirus vaccine boosted with a combination of 
Matrix-formulated Quil-A and virus-like particles. Such vaccine formulation 
effectively increased the immune responses and reduced the symptoms at 
challenge both after oral (Nguyen et al., 2003; Iosef et al., 2002) and intranasal 
(Azevedo et al., 2010; Nguyen et al., 2006a; Nguyen et al., 2006b; Gonzalez et 
al., 2004) administration. An attenuated live vaccine against Mycoplasma 
hyopneumoniae, intended for intrapulmonary injection, induced high antibody 
levels and cellular immune responses after intramuscular injection when 
adjuvanted with Matrix-formulated Quil-A (Xiong et al., 2014a). Compared to 
adjuvants based on carbomer, squalene or levamisole/chitosan, pigs receiving 
the vaccine with Matrix attained the highest cellular responses and had the 
lowest lung lesion scores after challenge (Xiong et al., 2014b). Thus, the pig is 
effective for studying saponin-based vaccines, but Matrix formulations based 
on less toxic fractions of Quil-A have not yet been evaluated. 
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1.3 The porcine innate immune system in adjuvant research 
Due to similarity in size, physiology, organ development and disease 
progression, the pig has been suggested as an ideal model for various human 
biomedical processes (Lunney, 2007). The pig is an outbred animal, but large-
sized litters allow to some extent correction for individual variations by 
distributing littermates in the experimental groups (Lunney, 2007). According 
to Dawson, H. (as cited in Schook et al., 2005), a comparison of the human, 
murine and porcine immune system revealed that more than 80% of the 
parameters analysed showed greatest similarities between pigs and humans, 
and less than 10% were more similar between mice and humans. A draft of the 
complete porcine genome (Ensembl build 10.2) was published in 2012 
(Groenen et al.), showing that the evolutionary rate in the pig is similar to that 
in man and other mammals, except the mouse that has at least the double 
evolutionary rate. Consequently, the porcine genome is more similar to the 
human than the murine is. Of 500 immune genes analysed in man, mouse and 
pig, the mouse had 178 unique genes, versus 34 in pigs and 49 in man (Dawson 
et al., 2013). Genomic similarity indicates functional similarity, and the main 
innate immune parameters likely to be affected by an immunomodulatory 
adjuvant will be discussed below for the pig. 
1.3.1 Pattern recognition receptors 
All major PRR families identified in human and mouse are present in the pig, 
including TLRs, NLRs, C-type lectin receptors, retinoic acid-inducible gene 
(RIG)-I-like receptors and absent in melanoma 2 (AIM2)-like receptors, with 
no large deviation in the number of genes compared to human (Dawson et al., 
2016). Overall, the PRRs identified are generally conserved between the pig 
and man. The importance of PRRs in porcine innate immunity is implied by 
the maintenance of a disproportionate amount of single-nucleotide 
polymorphisms located in the ligand-sensing parts of several porcine TLR 
genes, despite intensive breeding (Shinkai et al., 2006). Using gene 
knockdown or overexpression, many porcine PRRs have been shown to 
respond to ligands known for human and murine PRRs, as detailed below. 
TLRs are membrane-bound PRRs found on the cell surface (TLR1, -2, -4, -
5, -6, -10) and in endolysosomal compartments (TLR3, -7, -8, -9). They can 
form homodimers (TLR3-5, TLR7-9), heterodimers (TLR2/TLR1 and 
TLR2/TLR6) or complexes with other molecules (TLR4 and e.g. CD14). All 
TLRs except TLR3 signal through MyD88 and nuclear factor kappa-B 
(NF-κB) to induce proinflammatory cytokines and this pathway is used also in 
pigs, as shown for TLR2 and TLR4 (Tohno et al., 2007). Porcine TLR2 has 
ligands in common with its human counterpart (Alvarez et al., 2008) and has a 
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similar tissue and cellular distribution, being expressed where the host is likely 
to meet pathogens, such as the skin, bronchial epithelia and lymphoid tissue 
(Alvarez et al., 2008; Tohno et al., 2006). Monocyte-derived macrophages up-
regulate NF-κB-related genes after stimulation with the TLR4 agonist LPS 
(Kyrova et al., 2014). Furthermore, TLR4, MyD88 and NF-κB were involved 
in up-regulation of IL1B after in vitro infection of porcine alveolar 
macrophages with porcine reproductive and respiratory syndrome virus 
(PRRSV; Bi et al., 2014). Signalling via endosomal TLRs typically induce 
type I IFN after recognition of pathogen-derived nucleic acid; TLR3 through 
TIR-domain-containing adapter-inducing IFN-β (TRIF) and interferon 
regulatory factor (IRF)3/7 and TLR7 and TLR9 through MyD88 and IRF7. 
The requirement for these IRFs was confirmed for porcine TLR3 and TLR7 
using poly I:C and imiquimod as agonists and gene overexpression in a human 
cell line (Sang et al., 2008) and for TLR7 using gene knockdown in DCs 
(Alves et al., 2007). Imiquimod is a TLR7-specific agonist in humans and mice 
but activates both porcine TLR7 and TLR8 (Zhu et al., 2008). Porcine TLR9 is 
expressed in several lymphoid tissues and lack of expression was correlated 
with lack of responsiveness to CpG motifs (Dar et al., 2008; Tohno et al., 
2006). 
The RIG-I-like family consists of three cytosolic RNA sensors, including 
RIG-I itself. As for other species, porcine RIG-I was shown to signal through 
IRF3 and NF-κB, and RNA silencing of this receptor abolished the production 
of IFNα/β, IL-1β, IL-6 and TNF-α in porcine alveolar macrophages exposed 
to classical swine fever virus (Dong et al., 2013). Several other RNA viruses 
also induced IFN-β gene expression through RIG-I (Hüsser et al., 2011). 
The NOD-like receptors (NLRs) are a family of cytosolic sensors for both 
DAMPs and PAMPs and triggering of these receptors can activate the 
inflammasome and/or signal through IRFs and the NF-κB pathway (Zhong et 
al., 2013). Most known human NLRs were suggested from the porcine genome 
to be protein-coding genes also in the pig (Dawson et al., 2016), including one 
of the most studied such receptor, NLRP3. Several substances known to 
promote NLRP3 inflammasome formation in other species, such as alum, ATP, 
calcium pyrophosphate dihydrate crystals and nigericin, also activated the 
porcine NLRP3 inflammasome (Kim et al., 2014). 
The C-type lectin receptor dectin-1 is present in pigs (Sonck et al., 2009) 
and β-glucans trigger both dectin-1 and the complement receptor 3 but with 
some differences between cell types (Baert et al., 2015). Detailed knowledge 
on ligands and signalling for other porcine C-type lectin receptors is however 
scarce (Mair et al., 2014). 
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In the cytosol, DNA is detected by the inflammasome-forming AIM2-like 
receptors and stimulator of interferon genes (STING)-associated sensors that 
signal through IRF3 to trigger production of type I IFNs (Schlee & Hartmann, 
2016). Only two porcine AIM2-like receptor genes have been identified, 
MNDA and IFI16, and although sharing names with the human AIM2-like 
receptors, they are not orthologous (Dawson et al., 2016). The STING pathway 
has recently been described in other species as a central mediator for cytosolic 
DNA sensing that leads to type I IFN production (Schlee & Hartmann, 2016). 
In the pig, several cytosolic DNA sensors are expressed in various porcine 
tissues and were important for IFN-β induction by cytosolic DNA or 
pseudorabies virus in porcine cells (Wang et al., 2015; Zhu et al., 2014; Xie et 
al., 2010). Only one of them was shown specifically to signal through STING 
in the pig, although all cytosolic DNA sensors require STING in humans. 
However, all porcine cytosolic DNA sensors described require IRF3 for type I 
IFN induction, and their presence show that the DNA sensing system is present 
and functional also in the pig. 
Overall, many of the stimuli that activate innate immunity in other species 
can trigger porcine PRRs as well, and ligand specificities and down-stream 
signalling pathways generally seem to be comparable. Thus, the pig should 
respond to adjuvant formulations in a similar way as human and mouse. 
1.3.2 Mononuclear phagocyte system 
The mononuclear phagocyte system comprises some important innate immune 
cell types: monocytes, macrophages and DCs. These cells can, to a varying 
degree, initiate immune responses by production of cytokines and uptake of 
antigen for processing and presentation to lymphocytes. Categorization of cells 
belonging to the mononuclear phagocyte system has varied over time and been 
based on function, ontogeny or expression of cell markers, with no clear 
consensus (Vu Manh et al., 2015; Guilliams et al., 2014; Fairbairn et al., 
2011). Monocytes, macrophages and DCs constitute heterogeneous cell 
populations with a great plasticity and for many tissues there is no clear 
distinction between the populations, either in pigs, mice or humans (Vu Manh 
et al., 2015; Fairbairn et al., 2011; Summerfield & McCullough, 2009). 
Porcine blood monocytes have been classified into two or four 
differentiation stages, depending on cell markers used (Fairbairn et al., 2013; 
Chamorro et al., 2005). In vitro, porcine monocytes may up-regulate MHC II 
and increase the transcription of IL-10, IL-12, IL-13 and IFN-γ in response to 
LPS, and they can also respond to CpG (Raymond & Wilkie, 2005). 
Macrophages are tissue-resident cells that first encounter many of the 
pathogens. In vitro porcine macrophages can be generated with CSF-1 from 
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both monocytes and bone marrow, but their transcriptional responses to LPS 
differ prominently from those in alveolar macrophages (Kapetanovic et al., 
2013). In a study where porcine and murine bone marrow-derived 
macrophages were stimulated with LPS, the porcine responses were more 
similar to those of human monocyte-derived macrophages than the murine 
responses were (Kapetanovic et al., 2012). 
Dendritic cells are found both in blood and tissues and are roughly divided 
into conventional DCs and plasmacytoid DCs (pDCs). Plasmacytoid DCs are 
distinguished by their potent ability to produce IFN-α, whereas conventional 
DCs are typically defined as professional antigen-presenting cells. Porcine 
conventional DCs and pDCs are both present in blood with distinct phenotypes 
(Summerfield et al., 2003). In tissues, the conventional DCs express somewhat 
different cell markers depending on the location, and may not always be 
separated from other immune cells (Mair et al., 2014; Summerfield & 
McCullough, 2009). In porcine skin, four subsets of conventional DCs were 
described with various functional features (Marquet et al., 2014). 
To facilitate studies in porcine DCs, blood monocytes can be cultured with 
GM-CSF and IL-4 to generate monocyte-derived DCs (MoDCs; Johansson et 
al., 2003; Carrasco et al., 2001; Paillot et al., 2001). Although ontogenetically 
different, MoDCs are phenotypically similar to conventional DCs in blood and 
tissues, and share many of their functional features. The role of IL-4 in pigs has 
been disputed (Raymond & Wilkie, 2005) and replacing IL-4 with IL-13 in 
combination with GM-CSF also produced porcine MoDCs (Bautista et al., 
2007). Furthermore, DCs can be generated in vitro from bone marrow with 
GM-CSF (Carrasco et al., 2001) or with FMS-like tyrosine kinase-3 ligand 
(Guzylack-Piriou et al., 2010). Porcine MoDCs express the genes for TLR2 
(Alvarez et al., 2008), TLR3 (Auray et al., 2010) and TLR4 (Alvarez et al., 
2006) but low or no TRL5, -7 or -9 (Auray et al., 2010; Alves et al., 2007). 
Still, porcine MoDCs stimulated with LPS, poly I:C or imiquimod up-regulate 
the maturation markers CD80/86 (Auray et al., 2010), and exposure to agonists 
for TLR2-5 can induce production of pro-inflammatory cytokines (IL-6, TNF-
α), TH1 cytokines (IL-12, IFN-γ) and/or TH2 (IL-10, IL-13) cytokines (Auray 
et al., 2010; Raymond & Wilkie, 2005).  
Plasmacytoid DCs were originally identified as natural interferon-producing 
cells in porcine skin (Artursson et al., 1995) and intestine (Riffault et al., 
2001), and associated lymphoid tissues, as well as in blood (Domeika et al., 
2004; Summerfield et al., 2003). As in other species, porcine pDCs are cells 
that specifically respond to ligands for TLR7 and TLR9 by producing high 
levels of IFN-α, as well as IL-12 and TNF-α (Calzada-Nova et al., 2010; 
Guzylack-Piriou et al., 2004). Murine studies demonstrated that this is due to a 
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constitutive expression of IRF7 in pDCs (Honda et al., 2005). Activation of 
pDCs has been related to neutrophils in the pathological condition systemic 
lupus erythematosus. In this autoimmune disease, neutrophils are primed to 
release neutrophil extracellular traps (NETs) containing cathelicidins and self-
DNA that in turn activate pDCs through TLR9 (Garcia-Romo et al., 2011; 
Lande et al., 2011). Porcine neutrophils release NETs in a similar manner as 
human neutrophils (Brea et al., 2012; Scapinello et al., 2011) and porcine 
cathelicidins together with DNA have been shown to induce IFN-α production 
in pDCs (Baumann et al., 2014). 
Although no uniform subtyping of the cells belonging to the mononuclear 
phagocyte system exists, several lines of evidence suggest that there is no large 
discrepancy between the porcine system and those of other species. 
Furthermore, several in vitro systems are established that can be used to study 
immunomodulatory agents in the pig. 
1.3.3 Interferons and interferon-regulated genes 
The IFNs are a large family of cytokines with effects both on the innate and the 
adaptive immunity, especially regarding intracellular pathogens. Porcine IFNs 
consist of type I (IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-ω), type II (IFN-γ) 
and type III (IFN-λ) IFNs (Dawson et al., 2013; Wang et al., 2011). As in 
other species, porcine type I IFNs are known for their anti-viral properties. 
Type I IFN genes in pigs have undergone evolutionary expansion and contain 
two to three times as many genes as in human and mouse, including the eleven 
porcine-specific genes for IFN-δ (Dawson et al., 2013). At least 39 type I IFN 
genes and 16 pseudogenes exist in the pig (Dawson et al., 2013), with marked 
differences in gene expression between tissues (Sang et al., 2010). A large 
number of the porcine type I IFNs display antiviral effect in vitro against 
PRRSV or vesicular stomatitis virus (Sang et al., 2010) and IFN-α induction 
by poly I:C reduced the infectivity of PRRSV in alveolar macrophages (Miller 
et al., 2009). Vector-induced expression of IFN-α can under experimental 
conditions protect pigs against infection with foot-and-mouth disease virus 
(Moraes et al., 2003) and PRRSV (Brockmeier et al., 2009).  
Either type of IFN can induce an antiviral state in cells by inducing 
transcription of a large number of interferon-regulated genes (IRGs), including 
PRR genes (e.g. OAS1, RIG-I, most TLR genes) and those encoding IRFs and 
antiviral effectors (Schneider et al., 2014). In this way, IRG induction primes 
the cell for further pathogen sensing and production of IFN and simultaneously 
limits the virus infection. IFN type I and III induce IRGs via the IFN-
stimulated response elements (ISRE) promoter, whereas type II (IFN-γ) bind 
the gamma-activated sequence (GAS) promoter, resulting in different sets of 
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genes induced. The antiviral IRG products function either at the level of entry, 
replication or shedding of virus (Schneider et al., 2014). Broadly acting 
antiviral genes identified for human cells include IRF1, cGAS, RIG-I, MDA5 
and IFITM3 whereas other antiviral IRGs are either more or less virus-specific 
or exert their effect in combination with other IRGs (Schoggins et al., 2011). 
The number of IRGs induced is typically mentioned to be in the range of 
hundreds (Schneider et al., 2014; Schoggins et al., 2011). However, the 
Interferome database3 has to date identified over 3,000 IRGs each for type I 
and type II IFN by collecting data from high-throughput experiments of human 
and murine cells stimulated with IFN. Studies of this database show a large 
overlap of IRGs affected by type I and type II IFN. 
Many IRGs were induced in blood after injection with poly I:C in pigs, with 
more genes being affected in pigs with high IFN-α levels (Liu et al., 2014). 
Characterization of the numerous IRGs identified in various settings is often 
lacking, especially in the pig. However, the antiviral effect against PRRSV by 
type I IFN in porcine cells is to a great extent mediated through MX1 (Sang et 
al., 2010) and OAS1 has an inhibitory effect on PRRSV infection in vitro 
(Zhao et al., 2016). Studies using silencing RNA for OAS1, CXCL10, and 
NRAMP1 showed that these genes were involved in antiviral effects for 
classical swine fever virus (Wang et al., 2016). Induction of both IFN-α and 
IFN-γ in peripheral blood mononuclear cells (PBMCs) in vitro up-regulated the 
expression of CXCL10 (Dar et al., 2010), indicating that this gene is affected 
by both type I and type II IFN. But as IFN-α can stimulate porcine natural 
killer cells to produce IFN-γ (Toka et al., 2009), it may also promote up-
regulation of type II IFN-associated IRGs. 
In conclusion, the main types of PRRs and cells that respond to defined 
immunomodulatory adjuvants are present in the pig, and resemble what is 
found in man. Recently, the pig was suggested as an intermediate species 
between mouse and man for immunological studies (Dawson et al., 2016) and 
the pig should therefore be considered a suitable animal for adjuvant research.  
1.4 Gene expression profiling 
Immune cells respond to stimuli for example by secreting proteins or by 
changing their expression on or within the cell. Some of these proteins are 
preformed and released as full proteins or in processed forms. However, many 
proteins will require de novo synthesis after transcription of the corresponding 
gene. Several crucial events in immune cells thus occur at the level of 
transcription. Consequently, transcriptomics is a valuable tool alongside 
                                                        
3. http://www.interferome.org 
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proteomics and cellular profiling to examine host immune responses 
(Chaussabel et al., 2010). Indeed, a large number of immune related genes are 
transcribed in the response to pathogens (Jenner & Young, 2005; Huang et al., 
2001). Many of these genes are shared for different stimuli, but individuals 
typically respond in a stimuli-specific and cell type-specific manner with 
defined kinetics (Jenner & Young, 2005; Huang et al., 2001). Whereas 
quantitative real-time PCR (qPCR) remains the golden standard to measure 
transcription on a gene-to-gene basis, gene expression microarrays and RNA 
sequencing (RNA-Seq) allow for measuring the transcription of whole 
genomes without a pre-selection bias. This can be used to detect nuances of the 
responses to different pathogens or immunomodulatory agents. The first 
prototype microarray printed using robotics was a 48-probe array published in 
1995 (Schena et al.). Microarrays are based on probes of oligonucleotides or 
complementary DNA (cDNA) to which complementary sequences in the 
sample can hybridize. Each probe or set of probes generally represents one 
gene and tens of thousands probes may be spotted per array. Current 
microarrays typically cover the whole genome. An alternative method for 
large-scale measurements of messenger RNA (mRNA) is the RNA-Seq 
technology, which allows an even higher resolution by detecting splice variants 
(Schroyen & Tuggle, 2015; Wang et al., 2009).  
Microarray is a semi-quantitative method, but is effective to identify gene 
expression alterations, i.e. differentially expressed genes (DEGs)(Malone & 
Oliver, 2011; Allison et al., 2006). Gene expression profiling typically focus 
on identification of gene groups or functional pathways that are over-
represented, “enriched”, among these affected genes (Hedegaard 2009). With 
enrichment tools such as the Database for Annotation, Visualization and 
Integrated Discovery (DAVID)4 and Gene-Set Enrichment Analysis (GSEA)5, 
the gene expression of thousands of transcripts can be grouped based on 
functional annotations acquired from public databases, as Gene Ontology6 
(GO) or Kyoto Encyclopedia of Genes and Genomes (KEGG)7. Pathway 
analysis can be performed using for example Ingenuity Pathway Analysis 
(Qiagen) or InnateDB8, which apply known protein-protein interactions to 
make connections between the DEGs. Furthermore, principal component 
analysis and cluster analysis can be used to find similarities in expression 
between samples and/or genes (Allison et al., 2006). 
                                                        
4. https://david.ncifcrf.gov/ 
5. http://broadinstitute.org/gsea/ 
6. http://geneontology.org/ 
7. http://www.genome.jp/kegg/ 
8. http://www.innatedb.com/ 
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1.4.1 Transcriptomic profiling of adjuvant effects 
Host responses to pathogens and pathogen-derived molecules were explored by 
comparing a large number of already published microarray experiments on 
host-pathogen interactions (Jenner & Young, 2005). A common transcriptional 
response was identified and assigned to functional annotations such as (i) 
inflammatory cytokines, (ii) IRGs, (iii) transcription factors and signalling 
molecules that activate immune responses, (iv) anti-inflammatory factors, (v) 
lymphocyte activation, (vi) antigen presentation and (vii) cell adhesion (Jenner 
& Young, 2005). In a similar manner, a common set of “adjuvant core 
response” genes coding mainly for cytokines, chemokines and adhesion 
molecules were identified when analysing the global transcriptional response to 
the adjuvants alum, MF59 and CpG in injected mouse muscle (Mosca et al., 
2008). By revealing distinct differences in transcriptional responses to these 
adjuvants, the study emphasized that transcriptional profiling can provide 
insight into the mechanism of actions of adjuvants. Additionally, 
transcriptional changes could be related to increased protein expression in the 
tissue (Mosca et al., 2008). Another study, comparing the global transcriptional 
responses to a TH1-prone (monophosphoryl lipid A formulated in liposomes) 
and a TH2-prone (alum) adjuvant in peritoneal exudate cells from 
intraperitoneally injected mice, supported the idea that early gene signatures 
are related to the subsequent type of adaptive immune response (Korsholm et 
al., 2010).  
The host responses detected may vary considerably depending on the tissue 
sampled. Later microarray studies on adjuvant effects have revealed large 
differences in genes induced between injected muscle, draining lymph node 
and blood from the same animal (Caproni et al., 2012; Lambert et al., 2012). 
Gene signatures of adjuvants detected in vivo may also differ from those 
observed in vitro (Caproni et al., 2012). In humans, blood is the only easily 
accessible source for gene expression profiling of adjuvant responses in vivo. 
One way to overcome this limitation in mechanistic studies is to apply so 
called systems biology. Systems biology is the conceptual idea of combining 
traditional methods with emerging high-throughput methods in genomics, 
transcriptomics and proteomics for studies within the live animal, the whole 
“system” (Ideker et al., 2001). Transcriptional responses can be successfully 
detected in human blood after administration of adjuvant (Caskey et al., 2011) 
and together with antigen these gene expression signatures can be correlated 
with known immunological readouts (Pulendran et al., 2010). This method was 
applied for the yellow fever vaccine YF-17D, for which early transcription of 
specific genes could predict subsequent induction of antibody levels 
(TNFRS17) and CTL responses (GCN2) (Querec et al., 2009). This 
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computational procedure was later corroborated by studies in knockout mice 
revealing GCN2 to be a key modulator of cross-presentation in DCs 
(Ravindran et al., 2014). 
Results obtained from systems biology studies in various species and 
settings (Obermoser et al., 2013; Zak et al., 2012; Nakaya et al., 2011) support 
the notion that changes in gene expression are often associated with changes in 
protein expression and functional capacities. Consequently, this approach has 
recently also been used to find adjuvant-associated gene transcripts in blood 
that correlate with protection when combined with antigen (Nakaya et al., 
2016; Vaccari et al., 2016). Taken together, transcriptional changes are clearly 
related to type of inducer, type of cell or tissue analysed, and time after 
exposure. This supports the use of transcriptomics as a useful method to 
decipher mechanisms of vaccine adjuvant in vivo. 
1.4.2 Transcriptomic profiling of innate immune responses in the pig 
In the pig, genome-wide transcriptomics emerged around 2003 when 
commercial microarray platforms became available (Tuggle et al., 2007). The 
Qiagen NRSP8 porcine oligo array (designed in 2002) and the Affymetrix 
GeneChip porcine genome array (designed in 2004) were the first global arrays 
for pigs. Custom-made low-density spotted arrays containing less than 100 
genes focused on porcine immune responses have also been developed 
(Andersson et al., 2007; Ledger et al., 2004). During the past few years, RNA-
Seq has increased in popularity for porcine gene expression experiments, but 
the microarray technology is still more common (Fig. 1). The GeneChip array 
remains the most used microarray, but several genome-wide or immune-
specific platforms are available today (reviewed by Schroyen & Tuggle, 2015). 
The porcine genome was published in 2012 (Groenen et al.), but a 
comprehensive annotation of immune-related genes was lacking until recently 
(Dawson et al., 2016). As correct annotation is a hurdle in genome-wide 
transcriptomic studies in domestic animals (Hedegaard 2009), the full value of 
RNA-Seq for immunological studies has thereby been available for the pig. 
At the initiation of this thesis in 2010, no global transcriptomic studies on 
adjuvants or vaccines in the pig were available. Early immunological studies 
using genome-wide microarrays in the pigs focused on response to infections, 
such as Salmonella Cholerasuis using the NRSP8 array (Zhao et al., 2006) and 
studies on several pathogens using the GeneChip array: Salmonella 
Typhimurium (Wang et al., 2007), Salmonella Cholerasuis (Wang et al., 
2008), Haemophilus parasuis (Chen et al., 2009), classical swine fever virus 
(Durand et al., 2009) and porcine circovirus type 2 (PCV2) (Lee et al., 2010; 
Tomas et al., 2010). These studies identified genes and pathways previously 
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not associated with the diseases and genes involved in resistance to disease, in 
some cases. Furthermore, the NRSP8 array expanded with swine leukocyte 
antigen complex (porcine MHC) genes had been validated using porcine 
PBMCs stimulated in vitro with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin (Gao et al., 2010). Induction of cytokines and MHC genes recorded 
in that study could largely be confirmed by ELISA and flow cytometry. 
 
Figure 1. Porcine gene expression profiling studies over time. The graph displays number of 
deposited entries each year into the databases NCBI Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (https://www.ebi.ac.uk/arrayexpress/). Data 
acquired 2016-08-29. a Values for 2016 do not include the full year. 
The transcriptomic studies performed up to that point in 2010 suggested that 
the tools for global gene expression profiling in the pig were readily available 
and effective and could be used to study responses to adjuvants in vivo. 
Furthermore, the pig has multiple features that make it a suitable study subject 
for adjuvant research. In contrast to many other animals typically used, the size 
of pigs allow multiple sampling of large blood volumes in the same animal, 
which can be used to simultaneously assess gene transcription, serum 
components and cell subsets. It is also possible to collect tissue samples from 
sites of administration and immunologically active organs in pigs, which is 
more restricted for human subjects. There are also vaccination routines and 
infection models in the pig that can be used experimentally to assess the effect 
of adjuvants alone or in combination with antigen. These advantages were 
exploited in the current thesis to explore the innate immune responses to the 
saponin-based Matrix-M adjuvant. 
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2 Aim and objectives 
The aim of this thesis was to elucidate innate immune responses to the vaccine 
adjuvant Matrix-M in pigs, applying gene expression profiling. 
 
The specific objectives were to: 
Ø Establish methods for transcriptomic profiling of innate immune responses 
in porcine tissues 
Ø Identify clinical, haematological and histological effects of Matrix-M 
administration in pigs 
Ø Characterize the porcine transcriptional response to Matrix-M in vivo and 
in vitro 
Ø Assess possible mode of actions of Matrix-M in innate immunity 
Ø Evaluate prophylactic effects of Matrix-M in a porcine contact exposure 
model 
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3 Comments on material and methods 
An overview of material and methods and considerations regarding some of the 
methods used are presented below. For detailed descriptions, see each 
individual paper (Paper I – IV). 
3.1 Experimental designs 
3.1.1 Pigs 
To minimize unspecific activation of the immune system, effects of Matrix-M 
were studied exclusively in specific pathogen free (SPF) pigs and using blood 
cells collected from SPF pigs. Pigs aged nine to eleven weeks from two SPF 
herds were used. One of the SPF herds (Serogrisen; Ransta, Sweden) 
originated from caesarean-derived colostrum-deprived piglets (Wallgren et al., 
1999). Pigs from this herd were used in the two in vivo experiments with 
Matrix-M, performed at the animal facility of the National veterinary institute 
(Uppsala, Sweden; Paper II, IV). The other SPF herd (Swedish Livestock 
Research Centre; Lövsta-Uppsala, Sweden) was established in 2012 from the 
first SPF-herd, and these pigs were used for the in vitro studies with Matrix-M 
(Paper III, IV). The SPF herds were declared free from most major swine 
pathogens (Wallgren et al., 1999) but were known to harbour PCV2. Maternal 
antibodies to Haemophilus parasuis were found in the SPF herd used for the in 
vivo experiments (Paper IV). Both PCV2 and H. parasuis may induce disease 
in the presence of environmental stressors, but no clinical signs of disease 
associated with PCV2 or H. parasuis were present in the SPF herds. 
Conventionally reared pigs were used for a contact exposure model (Paper 
IV). The health status of pigs in Sweden is generally high, but common 
pathogens in conventional pig farms causing respiratory or systemic disease 
include Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, 
Pasteurella multocida, Streptococcus suis and H. parasuis. PCV2 is present in 
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most herds, but herds that have experienced PCV2-associated diseases are 
generally vaccinated against PCV2. PRRSV has not been reported in Sweden 
since 20079. All of the listed pathogens are involved in the so-called “porcine 
respiratory disease complex” that may interact with stressors from environment 
and management to induce disease in for example grower pigs (Opriessnig et 
al., 2011). The conventionally reared pigs used in Paper IV originated from a 
farrow-to-finish herd with a high prevalence of respiratory lesions recorded at 
slaughter. These pigs had typically high levels of serum antibodies to A. 
pleuropneumoniae and to P. multocida at 19 weeks of age and PCV2 was 
known to be present in the herd, although without clinical signs of PCV2-
associated disease. Thus, it was assumed that any SPF pigs mixed with these 
pigs would develop respiratory and/or systemic disease with time. 
3.1.2 Administration of Matrix M and contact exposure model 
All experiments were carried out with Matrix-M (AbISCO-100) except in the 
tolerability study in which Matrix-Q (AbISCO-300) was used. Matrix-Q was 
administered subcutaneously in three dosage options (75 µg, 100 µg, 150 µg; 
Paper III) whereas 150 µg of Matrix-M was injected intramuscularly (Paper II, 
IV). Doses were based on published data and previous experience from other 
species. In comparison, the Matrix-M dose used in human clinical trials is 50 
µg (Cox et al., 2011). The adjuvants were obtained from Isconova AB that is 
currently acquired by Novavax Inc. Matrix-M was suspended in saline to 
minimize irritation from the vehicle and was administered intramuscularly into 
the thigh to be able to locate the injection site and the draining lymph node(s) 
(Paper II, IV). Matrix-Q was given subcutaneously to better be able to assess 
the local reaction (Paper III).  
The early local immune response to Matrix-M (Paper II) was evaluated in 
SPF pigs exposed to as few stressors as possible. The pigs were allocated into 
groups at the farm of origin 14 days before delivery and given a 48-hour 
acclimatization period after the transport to the animal facility before 
administration of Matrix-M or saline. The pigs were sacrificed 24 hours later 
because mice injected with various adjuvants had the greatest number of genes 
up-regulated in muscle after 24 hours (Mosca et al., 2008). Also sheep 
administered ISCOMATRIX displayed maximum lymph node reaction 24 
hours after injection coinciding with maximum cytokine output at this time 
(Windon et al., 2000). Thus, 24 hours after injection of Matrix-M was chosen 
as an appropriate time point for detection of changes both at the injection site 
and in the draining lymph node. 
                                                        
9. http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/Diseasedistributionmap/ 
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In Paper IV, the effect of Matrix-M on stress induced by transport and 
mixing coupled with contact exposure to pigs with different health status was 
evaluated. In order to mimic field conditions experimentally, SPF pigs were 
co-mingled with conventionally reared pig or with non-littermate SPF-pigs. No 
acclimatization period was applied and these SPF pigs were administered 
Matrix-M at the farm of origin the day before transport to the animal facility. 
Four hours after arrival, the SPF pigs were mixed with conventionally reared 
pigs. The experiment was designed to follow the transcriptional response to 
Matrix-M in blood but was adapted in length with the aim to still have active 
transcriptional responses to Matrix-M in the local tissues at the termination. 
Thus, all pigs were sacrificed six days after injections. 
3.1.3 Evaluation of adjuvant reaction and disease parameters 
The general condition of the pigs and adverse reaction at the injection site was 
assessed in all in vivo experiments (Paper II, III, IV). At post-mortem 
examination, the muscle at the injection site and its draining iliac lymph node 
was specifically examined for macroscopical alterations to detect reactions to 
Matrix-M (Paper II, IV). As the SPF pigs in Paper IV were assumed to develop 
illness due to the contact exposure to conventionally reared pigs differential 
WBC and serum levels of SAA were used to follow the disease progression in 
blood (Cray et al., 2009; Hulten et al., 2003). Respiratory signs were recorded 
for these pigs using a scale from 0 to 3 and criteria previously applied in 
experimental infection with A. pleuropneumoniae (Sjolund et al., 2009). Post 
mortem, lesions in bronchial lymph nodes, lung and joints were recorded as 
indications of infectious disease (Paper IV). 
3.1.4 Tissue sampling and histological evaluation 
Tissue samples from the muscle at injection sites and internal iliac lymph 
nodes were collected immediately after death (Paper II, IV). Samples were 
transferred to RNAlater and kept overnight at 4°C followed by long-term 
storage at -70°C (according to manufacturer’s directions), snap-frozen in dry 
ice-cooled isopentane before immediate long-term storage in liquid nitrogen, or 
fixed in formalin. RNAlater allow quick stabilization of the RNA in the tissue 
and storage at ambient temperatures for limited periods, at least a week 
according to the manufacturer. RNAlater is also useful to limit degradation 
when thawing the samples for RNA extraction. Formalin-fixed samples were 
embedded in paraffin and sections were stained with haematoxylin and eosin 
for histological evaluation, which was done in collaboration with a senior 
veterinary pathologist (Paper II). Thus, precautions were taken to limit the 
destruction of RNA and to preserve samples for putative future analysis. 
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3.2 In vitro exposure to Matrix-M 
3.2.1 Stimulation of cell cultures for gene expression analysis 
PBMCs that are commonly used to study immune reactivity in vitro were used 
to measure transcriptional responses to Matrix-M (Paper III and IV). As not all 
cells are likely to take part in the response, or respond in a similar fashion, 
subpopulations of PBMCs were established by in vitro depletion, enrichment 
or differentiation. Because DCs are critical for a strong adaptive immune 
response and may be targeted by vaccine adjuvants (Liang & Lore, 2016), 
MoDCs were generated for exposure to Matrix-M. Monocytes were also used 
for Matrix-M exposure studies. 
Blood collected from SPF pigs in heparinized tubes, to reduce clotting, was 
processed within one hour to reduce non-specific activation of cells (Paper III, 
IV). PBMCs were isolated by centrifugation on Ficoll-Paque PLUS and 
monocytes were isolated from PBMCs by plastic adherence. MoDCs were 
generated by culturing monocytes for five days in the presence of rpIL-4 and 
rpGM-SCF, as previously described (Johansson et al., 2003; Carrasco et al., 
2001; Paillot et al., 2001). MoDCs generated in this way express several TLRs 
and can be induced to produce both pro-inflammatory cytokines and IFN-α 
(Auray et al., 2010; Johansson et al., 2003), and they are efficient at both 
receptor- and non-receptor-mediated endocytosis (Paillot et al., 2001). Plastic 
adherence of human monocytes for generation of MoDCs has been reported to 
affect their cytokine expression (Elkord et al., 2005), but this effect was not 
detected for porcine MoDCs (Auray et al., 2010). 
Cell cultures were exposed to Matrix-M, LPS or ODN 2216 (Paper III, IV). 
Short-term 6-hour exposures were made for freshly isolated PBMCs (Paper 
III), monocytes cultured overnight, lymphocytes cultured overnight or for three 
days and MoDC generated for five days (Paper IV). The transcriptional host 
response to immunomodulatory agents typically follows a temporal pattern 
(Jenner & Young, 2005), and gene transcripts induced by Matrix-M may 
escape detection at a short-term exposure. Long-term exposures were therefore 
made for lymphocytes and MoDCs. This allowed the cells to respond not only 
to Matrix-M directly, but also to molecules promoted initially by Matrix-M and 
possibly to DAMPs released from the cells. 
3.2.2 Induction of neutrophil extracellular traps 
Isolation of porcine polymorphonuclear leukocytes was made after removal of 
erythrocytes from blood by dextran sulphate by using a discontinuous gradient 
of 70% and 80% Percoll (Paper III; Dom et al., 1992). The pre-removal of 
erythrocytes was essential since a gradient alone will not certify a complete 
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separation between polymorphonuclear leukocytes and erythrocytes in porcine 
blood (Roberts et al., 1987). Polymorphonuclear leukocytes experiments were 
performed in serum-free media, since nucleases that degrade NETs may be 
present in serum (von Kockritz-Blickwede et al., 2009). Instead, 2% BSA was 
used to facilitate adherence of neutrophils (Brinkmann et al., 2010). The best 
known inducer of NETs is PMA and the concentration used in the current 
thesis has been described to produce NET-like structures from porcine 
neutrophils (Scapinello et al., 2011). Matrix-M was tested in various 
concentrations: 0.3, 1 and 3 µg/ml. After stimulation for four hours, culture 
media was removed and DNA was visualized by addition of SYTOX Green for 
10 min followed by fixation with formaldehyde for 30 min, both in dark. 
Although SYTOX Green is non-permeable, this method allowed for staining of 
both extracellular and intracellular DNA with SYTOX without disrupting the 
sensitive NET-like structures. 
3.3 Gene expression analysis 
Microarray technology was used to measure the global transcriptional response 
to Matrix-M in muscle and draining lymph node, providing an unbiased gene 
expression profile (Paper II). Prior to this, the same microarray was applied to 
intestinal tissue obtained from pigs experimentally infected with PCV2 and 
porcine parvovirus (PPV) in order to consider the method and gain experience 
in evaluating the data generated (Paper I). The microarray analyses were 
complemented with qPCR analysis in these two studies. The transcriptional 
response in blood to Matrix-M administration was screened with a qPCR plate 
array, and selected up-regulated genes were confirmed by single qPCR assays 
(Paper IV). Expression in cell cultures exposed to Matrix-M or other inducers 
was also measured with qPCR (Paper III, IV). 
3.3.1 RNA isolation 
RNA from cell cultures and all tissues except blood was extracted using a 
combination of Trizol reagent and RNA purification spin columns (Paper I, II, 
III, IV) described by Wikström et al. (2011). This method avoids the use of 
homogenization columns, reduces the risk of contamination from Trizol, and 
allows DNA to be acquired from the same samples (Paper I). Muscle samples 
were homogenized in Trizol by a stator-rotor homogenizer and samples from 
intestine and draining lymph nodes were homogenized in Trizol using a 
mechanized pestle and passing through an 18G needle multiple times. The 
pestle disrupted muscle and connective tissue to a low degree, which enriched 
samples for RNA from immune cells. Cell cultures were homogenized by 
 38 
repeatedly pipetting the Trizol mixture up and down. All cell and tissue 
homogenates were brought up in 1 ml Trizol to make the downstream protocol 
equal regardless of source. After phase separation, the RNA-containing 
aqueous phase was loaded onto E.Z.N.A Total RNA Kit columns for 
purification of the RNA. 
PAXgene Blood RNA Tubes that immediately stabilize RNA were used to 
collect whole blood for gene expression analysis (Paper IV), and the 
corresponding PAXgene Blood RNA Kit was used for RNA isolation. These 
tubes are designed for human use and proved somewhat difficult to use in pigs. 
The amount of blood collected in these tubes is normally limited and did also 
not always fill up completely, leading to low RNA yield for some samples. 
These RNA samples were further concentrated by the E.Z.N.A. MicroElute 
RNA Clean Up Kit. 
3.3.2 RNA quality control 
Quantity (260 nm) and purity (260/230 and 260/280) of isolated RNA was 
determined by absorbance using a Nanodrop spectrophotometer. Quite a few 
samples were below the recommended ratio of 1.8 for 260/230, especially 
RNA samples from in vitro experiments or those with low yield. No correlation 
was found between low 260/230 ratios and qPCR efficiency, as estimated both 
by LinRegPCR10 and expression analysis of reference genes. As possible 
contaminants not seemed to affect the qPCR reaction, no cut-off was used 
based on purity as assessed by the absorbance values.  
The quality of RNA from in vivo samples was measured by the capillary 
gel electrophoresis systems Bioanalyzer (Paper I, II) and Experion (Paper IV), 
which score the RNA integrity on a scale from 1 to 10 as an RNA Integrity 
Number (RIN) or an RNA Quality Indicator (RQI), where intact RNA have 
RIN > 8 (Fleige & Pfaffl, 2006). RIN and RQI values are calculated slightly 
different but give comparable results (Pfaffl et al., 2008). The quality of all 
samples for microarray analysis (Paper I, II) was analyzed, but was not 
routinely performed for all other samples. RNA samples from intestine from 
the PCV2-infected pigs (Paper I) displayed large variation in integrity and the 
three samples from each group with the highest RIN were selected for 
microarray analysis (RIN 6.2 – 7.8). Average RIN values reported from bovine 
intestines ranged from 4.6 to 7.5 (Fleige & Pfaffl, 2006). RNA from the 
Matrix-M in vivo experiment (Paper II) was extracted from tissue samples 
stored in RNAlater and displayed RIN values from injection site ranging from 
7.4 – 9.4 and from draining lymph node ranging from 7.2 – 9.5. A 
representative selection of blood RNA samples was evaluated in Paper IV, 
                                                        
10. http://www.linregpcr.nl/ 
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indicating a high quality (RQI > 8) of the RNA isolated and purified with the 
applied method. 
3.3.3 Synthesis of cDNA 
Due to various numbers of cells in the cell cultures and varying amount of 
tissue prepared, different amounts of RNA was used for the synthesis of 
cDNA. Equal amounts of RNA were used within each experiment to facilitate 
comparisons between treated and untreated samples. Despite separation of 
RNA from DNA using Trizol or on-column DNase treatment with the 
PAXgene kit, contamination with genomic DNA was still possible. Intron-
spanning qPCR assays are unaffected by genomic DNA contamination, but 
many genes do not allow such primer design. Thus, genomic DNA had to be 
kept at a minimum. RNA samples isolated using Trizol were treated with 
RNase-free DNase (Promega) before cDNA synthesis, but PAXgene-isolated 
RNA was degraded during the heat-inactivation step. The DNA-free DNA 
Removal Kit that applies protein precipitation for DNase inactivation was 
therefore used for the PAXgene RNA. 
First strand cDNA was synthesised using Superscript II Reverse 
Transcriptase (Paper I, II, III;) or the GoScript Reverse Transcription System 
(Paper III, IV). To confirm the removal of genomic DNA, an intron-less IFN-α 
qPCR assay was performed on non-reverse transcribed control samples (Trizol 
samples) or on the DNased RNA (PAXgene samples). 
3.3.4 Reverse transcription qPCR 
In Paper I, II and the in vitro part of Paper III, qPCR assays based on 
hydrolysis probes (TaqMan) previously established in the lab were used for 
gene expression analysis (Wikström et al., 2011; Timmusk et al., 2009). In 
Paper IV and the in vivo part of Paper III, SYBR Green qPCR assays were 
used. Assays based on hydrolysis probes may be more specific than SYBR 
Green, but lack the possibility for melt-curve analysis. SYBR Green binds any 
DNA and can cause accidental false positives due to non-specific amplicons or 
primer-dimers, but analysing the melt curve can identify these. As long as both 
methods are specific, they provide equal estimation of gene expression 
(Arikawa et al., 2008). Non-specific products for the SYBR Green qPCR assay 
were rare in the optimized assays in the current thesis, except for late appearing 
(high Cq) products in no-template control reactions. Primer pairs for SYBR 
Green qPCR were taken from the hydrolysis probe assays (IFN-α, IFN-γ, 
IL1B, IL6, IL10, IL12B, TNF, TGFB1), from published works (GAPDH, 
HPRT, IFN-β, PPIA, RPL32, SPP1, STING, TLR2, TLR4, YWHAZ) or were 
designed in house (CXCL8, IFITM3, IL17A). All primer pairs were optimized 
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or re-optimized for the current SYBR Green qPCR kit and qPCR platform 
(Table 1 in Paper III, Table 1 in Paper IV). A custom SYBR Green qPCR plate 
array containing 92 innate immunity genes was used for screening of gene 
expression in blood after Matrix-M administration (Paper IV). Genes on the 
array were selected based on general knowledge on innate immune responses 
as well as genes indicated from the microarray study, and included for example 
genes for interleukins, IFNs, IRGs, chemokines and chemokine receptors, 
PRRs and associated adaptor proteins and transcription factors. Due to the 
number of total samples (8 pigs, 6 time points), pooled RNA from each group 
was used for discovery of possible DEGs, which were selected for further 
validation. A number of genes (IL18, MYD88, NLRP3, TLR4 and TLR9) from 
the plate were analysed on individual samples using the same commercial 
assay in single assay format. 
All hydrolysis probe assays were run in triplicates, whereas SYBR Green 
assays were run in duplicates. Triplicates allow for removing outliers but 
duplicates need to be reanalysed in case of diverging results. However, the 
variability between replicates was typically low, which supported the use of 
only duplicates. Melt curve analysis was performed after each SYBR Green 
qPCR run. Limit of detection was not established despite being recommended 
in the MIQE guidelines (Bustin et al., 2009). For the SYBR Green assays, 
samples were regarded as not detected or non-quantifiable if Cq > 35 for either 
replicate or if there were large differences between replicates for samples with 
high Cq values. 
3.3.5 Reference genes and normalisation of gene expression 
Differences in RNA quality, RNA amount in the cDNA synthesis and 
effectiveness of the cDNA synthesis reaction will affect the threshold cycle 
values obtained for all genes analysed in a sample. Normalising Cq values for 
genes of interest against the expression of reference genes can correct for this. 
Reference genes are selected among genes that have stable expression despite 
experimental treatment. Using several reference genes reduce the risk of errors, 
especially when detecting small differences in expression (Vandesompele et 
al., 2002). As this was anticipated for gene expression in blood (Paper IV), a 
number of reference gene candidates were tested using the geNorm algorithm 
in the software qBase+. The algorithm uses a pair-wise exclusion approach to 
select the most stably expressed genes in a data set. The genes GAPDH, HPRT, 
PPIA, RPL32 and YWHAZ were evaluated, of which PPIA and RPL32 
displayed the most stable gene expression (M value = 0.345) and were used in 
further gene expression analysis of blood samples. 
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The relative gene expression was calculated using the 2−∆∆Cq method (Livak 
& Schmittgen, 2001), using a geometric average of several reference genes 
(Vandesompele et al., 2002). The ∆∆Cq is the difference in Cq for a gene of 
interest between a sample and a calibrator sample, corrected for the Cq 
difference of the reference gene(s). The formula 2−∆∆Cq provides the fold 
change (FC) in expression between the two samples, assuming equal efficiency 
of gene of interest and reference genes in the qPCR reactions. 
3.3.6 Gene expression profiling using microarray 
Microarray analysis with the Affymetrix GeneChip Porcine Genome Array was 
performed at the Uppsala Array Platform (Paper I, II) according to the 
manufacturer’s instructions. To find DEGs between groups, the empirical 
Bayes moderated t-test was applied using the limma package (Smyth, 2005). 
This method utilizes the variance from the whole array for each gene, which 
overcomes the problem of small sample sizes. Multiple testing was corrected 
for using the method of Benjamini and Hochberg (1995), which provide a false 
discovery rate (q-value) for each gene. The false discovery rate method gives 
an estimation of the number of false positives among the genes detected as 
differentially expressed on the microarray. This is preferred to traditional 
multiple testing methods that calculate an adjusted p-value based on the risk of 
finding a single false positive among all genes, which may be too conservative 
to find any DEGs (Allison et al., 2006). Principal component analysis of the 
gene expression was also performed to provide a graphical overview of 
similarity in expression between samples. 
Functional enrichment analysis based on DEGs was performed with the 
web-based program DAVID using gene lists from GO and KEGG (Paper I, II). 
GO terms were also used to identify genes related to specific functions, 
especially cytokines and cytokine binding (Paper II). No suitable GO terms 
were available for some functions, so gene lists from the literature was used to 
identify PRRs (Lee & Kim, 2007), IRGs (Jenner & Young, 2005) and 
conserved gene signatures of leukocyte subpopulations (Robbins et al., 2008). 
GSEA was used for enrichment analysis in cases where manually selected gene 
lists were required (Paper II), as this was not possible in DAVID. GSEA uses a 
completely different computational approach, taking into account the relative 
expression of all the genes on the array when calculation enrichment of genes. 
However, GSEA and the method used by DAVID typically provide similar 
results (Huang da et al., 2009). In Paper I, cluster analysis was performed and 
visualized with a heatmap to identify genes with similar or diverging 
expression between the two PCV2 isolates. Clustering is useful when 
comparing multiple experimental groups or samples against each other. 
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However, the results from muscle and draining lymph node in response to 
Matrix-M were too diverging to produce meaningful clustering (Paper II).  
Validation of findings from microarray results is often made by re-
analysing the same sample with a more sensitive method, commonly qPCR. 
The value of this type of validation may be limited, since a systematic bias is 
required to affect identification of DEGs (Allison et al., 2006). However, the 
estimated relative expression might differ as microarrays are semi-quantitative 
(Arikawa et al., 2008). Further, microarrays and qPCR are not equivalent and 
may detect different transcript variants when analysing the same gene (Tuggle 
et al., 2007). Thus, results obtained by microarray and qPCR may not correlate, 
even though neither is incorrect. No validation was performed for microarray 
on PCV2-infected intestine (Paper I), whereas a number of genes detected by 
microarray in response to Matrix-M were analysed by qPCR (Paper II). 
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4 Results and discussion 
4.1 Clinical, haematological and histological effects of Matrix-M 
(Paper II, III, IV) 
The saponin adjuvant formulation Matrix-M is known to have a good safety 
and tolerability in humans (Cox et al., 2011). Still, a local reaction at the site of 
injection is to be expected, as well as reactions in the local draining lymph 
node where the adaptive immune response develops. Reactions to Matrix-M 
and related formulations have been evaluated extensively in mice, but there are 
few reports of early innate immune responses in larger animals that may better 
reflect those in humans. Therefore, the tolerability and early inflammatory 
response to Matrix formulations were evaluated in the pig. 
Matrix-Q made from non-fractionated Quil-A is considered more 
reactogenic than the Matrix-M used in experimental human vaccines. The 
tolerability of subcutaneously injected Matrix-Q at concentrations of 75, 100 
and 150 µg was evaluated in one-week old piglets (n = 3) followed for 30 
hours (Paper III). No local adverse reactions or decrease in activity was 
detected in any of the pigs, but one pig given the lowest dose had a low-grade 
fever 30 hours after administration. Nor did Matrix-M at a intramuscular 
injection of 150 µg provoke any adverse effects in pigs aged 9 to 11 weeks, 
when followed for 24 hours (Paper II) or 6 days (Paper IV). The Matrix-M 
dose of 150 µg was three times higher than the dose used in human clinical 
trials, for which both good humoral (Cox et al., 2011) and cellular (Pedersen et 
al., 2014) immune responses were attained when combined with antigen. Both 
Matrix-M and Matrix-Q should thus be regarded as well tolerated by pigs. 
Resident immune cells, such as macrophages and DCs, are rare in muscle 
tissue during physiological conditions and recruitment of leukocytes to the 
injection site is essential for development of protection to antigens (Liang & 
Lore, 2016). Dissection of the injection site one day after intramuscular 
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administration of Matrix-M showed redness in the injected muscle, indicating a 
local reaction (Paper II). Histologically, all Matrix-M injected pigs displayed 
various degrees of local inflammation that was not recorded in any of the 
control pigs injected with saline. The inflammation was mainly characterized 
by infiltration of neutrophils, but also lymphocytes and macrophages were 
present. ISCOMs (Watson et al., 1989) and ISCOMATRIX (Wilson et al., 
2012) promote recruitment of immune competent cells to the site of 
administration. Also the particulate adjuvants alum and MF59 increase the 
numbers of multiple cell types in the muscle within a day after administration, 
of which neutrophils are the first to be recruited (Calabro et al., 2011). In 
contrast, the TLR agonist adjuvants resiquimod and CpG promoted little or no 
recruitment of cells to injected muscle in mice (Caproni et al., 2012), placing 
Matrix-M more in line with other particulate adjuvants. 
Transport of antigen to the draining lymph node is crucial for induction of 
an adaptive immune response, but Matrix-M injection induced a prominent 
reaction of the draining lymph node in pigs also in the absence of any co-
administered antigen. Three out of six pigs had enlarged lymph nodes 24 hours 
after administration, compared to one out of six pigs that received saline (Paper 
II). Histological examinations revealed a reactive lymphoid hyperplasia in four 
of the six Matrix-M pigs, which was absent in pigs given saline. Even six days 
after administration, a reaction in the draining lymph node was detected at 
gross pathology in four out of eight pigs that had received Matrix-M (Paper 
IV). In mice, granulocyte numbers increased considerably in the draining 
lymph node after subcutaneous injection with both Matrix-M (Reimer et al., 
2012) and ISCOMATRIX (Duewell et al., 2011). In pigs, histological 
examination of the draining lymph nodes suggested an influx of eosinophils 24 
hours after Matrix-M administration (Paper II), as previously described in mice 
after injection with MF59 (Calabro et al., 2011). In mice, also DCs, B and T 
cells were reported to increase in draining lymph node after Matrix-M 
administration (Reimer et al., 2012), but no such characterizations were made 
in the present thesis. 
Matrix-M seem to be well tolerated by pigs at doses used clinically in 
vaccines. Intramuscular injections with Matrix-M promoted cell recruitment 
both to the injection site and draining lymph nodes without showing any 
clinical signs of illness or discomfort following injection. Thus, the recorded 
cell migration indicated that Matrix-M elicit a mild inflammation with 
production of immune mediators that promote recruitment, activation and 
differentiation of effector cell populations.  
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4.2 Gene expression profiling of innate immune responses in 
pigs (Paper I, II, IV)  
The host response to pathogens and pathogen-derived molecules encompass 
transcription of many more genes than traditionally measured in 
immunological studies, and each stimuli may produce different expression 
profiles (Jenner & Young, 2005). To get an unbiased characterization of the 
response to Matrix-M, the Affymetrix GeneChip Porcine Genome Array was 
applied (Paper II). Archived material from PCV2-infected pigs was used to 
establish necessary methods for this application (Paper I). The focus was to 
generate RNA of sufficient quality from relevant tissues for this type of 
analysis and to learn how to extract relevant knowledge from the data. 
Furthermore, qPCR methods were elaborated to confirm and refine results 
from the GeneChip array. In addition, a porcine 92-gene qPCR plate array was 
used to profile the kinetic of transcriptomic responses in blood for five days 
following Matrix-M injection (Paper IV). 
The transcriptional response in the intestine was measured in pigs co-
infected with either of two PCV2 isolates (S-PCV2 or PCV2-1010) and PPV, 
compared to PPV only or to uninfected controls (n = 3; Paper I). Of the 23,256 
probesets on the GeneChip array, 14,411 detected expression in pigs from all 
four groups. Principal component analysis revealed that the response in one pig 
from each infected group deviated considerably from the other two and had to 
be excluded in all subsequent analyses, except the GO term enrichment 
analysis. Biological variation, possibly due to the late sampling time at 28 days 
post-infection, also prohibited the use of a cut-off for DEGs based on false 
discovery rate and instead the p-value was used together with FC (FC > 2; p < 
0.01). At that time PCV2-associated disease may appear but with a great inter-
individual variation and a low statistical and biological significance (FC > 1.5; 
p < 0.05) was used as cut-off for DEGs in the response to PCV2 in the draining 
lymph node 21 days after infection (Lee et al., 2010). When selecting DEGs, a 
criterion based on a combination of FC and q-value is preferred (Allison et al., 
2006), but FC alone may be used if the goal is to find genes for functional 
enrichment analysis (Shi et al., 2008). 
Based on gene annotations from Tsai et al. (2006) and GO terms for 
functional annotation, enrichment analysis of DEGs revealed the process 
immune response to be significantly up-regulated in both PCV2 groups, and 
inflammatory response, defense response and complement activation in the 
S-PCV2/PPV group. Cluster analysis visualized by a heatmap (Fig. 2 in 
Paper I) revealed a much larger number of down-regulated genes in the 
S-PCV2/PPV group than in the PCV2-1010/PPV group. Many of these genes 
are involved in metabolism and regulation of catabolic processes, which may 
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reflect the tendency of a more severe pathology, recorded in the S-PCV2/PPV 
infected pigs. On the other hand, both PCV2-infected groups shared IFITM3 as 
the most up-regulated gene. This IRG and antiviral gene (Everitt et al., 2012) 
had a FC 5 to 7 times higher than the second most up-regulated gene in either 
group. Despite induction of several other IRGs, IFITM3 was not reported as 
up-regulated in intestinal lymph nodes in a time-course study on PCV2 (Tomas 
et al., 2010). IFITM3 may therefore be identified as a gene unique for the 
intestine. Thus, insight into the response to PCV2 was gained despite a 
biological variation that limited the evaluation of data. It was concluded that 
the GeneChip array was useful to study transcriptional host responses in 
porcine tissues. 
The transcriptional response to Matrix-M was analysed 24 hours after 
intramuscular injection and a total of 17,611 and 18,666 probesets detected 
expression in samples from the injection site and the draining lymph node, 
respectively. Differentially expressed genes for Matrix-M compared to saline 
were identified using a cut-off based on both FC and false discovery rate (FC > 
2; q < 0.05; n = 3; Paper II). By correcting for redundant probesets, 546 genes 
were found differentially regulated in the injected muscle and 309 genes in the 
draining lymph node. Injection with the adjuvants MF59, alum or CpG in 
murine muscle have previously identified a number of “adjuvant core response 
genes” common for all three adjuvants at the injection site (Mosca et al., 
2008). On the porcine GeneChip array, 61 homologues to the “adjuvant core 
response genes” were present and 20 of these were differentially expressed by 
Matrix-M. Enrichment analysis on the Matrix-M response revealed 38 GO 
terms to be enriched in the muscle and 4 in the draining lymph node of which 
the terms immune response and defense response were among the top three 
enriched in both groups. 
To study the response in blood over a period of five days in pigs injected 
with Matrix-M, a custom 92-gene qPCR plate array that focused on innate 
immunity was used on pooled blood samples (n = 4; Paper IV). About 30% of 
the genes on the array were up-regulated at any time point in both Matrix-M 
and saline administered pigs. This clearly reflected the setup of the experiment, 
where pigs were transported and mixed with non-littermates 18 hours after 
injection. These stressors are known to affect blood parameters in pigs such as 
cortisol, granulocytes (Dalin et al., 1993) and acute-phase proteins (Salamano 
et al., 2008; Pineiro et al., 2007), which also complicated interpretation of the 
gene expression results. However, a delay of the induction of gene expression 
was indicated for the saline injected pigs. Comparing the FC values at 18 hours 
post injection revealed a relative up-regulation (> 2-fold expression) in 
Matrix-M injected pigs compared to saline for 19 genes. Five of these genes 
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(IL18, MYD88, NLRP3, TLR4, TLR9) were subjected to validation on 
individual samples collected from all pigs in the study at 18-hours after 
administration (n = 8), but none of the genes were significantly up-regulated. It 
is possible that the non-normal distribution of gene expression levels (Kubista 
et al., 2006) skewed the results from the qPCR plate array when pooling 
samples. 
In conclusion, the GeneChip array detected immunological perturbations in 
pigs in vivo and annotations based on homologous human gene names 
facilitated the functional enrichment analysis using GO terms. The DEGs and 
enriched GO terms detected for PCV2 were in accordance with clinical 
findings but also emphasized the need to reduce the biological variation by 
careful experimental design. Indeed, the gene expression in response to 
Matrix-M adjuvant measured 24 hours after administration was rather uniform 
and identified activation of genes related to the innate immune system in a way 
that motivated deeper analysis. 
4.3 Gene expression in SPF pigs after Matrix-M administration 
(Paper II, III, IV) 
A large number of genes were affected locally after Matrix-M administration. 
The cellular processes at the injection site and in the draining lymph node 
suggested cytokines and chemokines to be involved in the response. GO terms 
were used to identify such genes in the microarray data, and a total of 19 genes 
coding for cytokines or cytokine binding proteins were differentially expressed 
at the injection site 24 hours after Matrix-M administration (Table 5 in 
Paper II). In the draining lymph node, 11 such genes were affected. Of several 
adjuvants evaluated in mice, only the TRL2 agonist Pam3CSK4 regulated a 
substantial amount of cytokines both at the injection site and in the draining 
lymph node (Caproni et al., 2012). Other adjuvants in that study either affected 
cytokine genes solely at the injection site (MF59, alum, CpG), or 
predominantly in the draining lymph node (resiquimod). This separates 
Matrix-M from other particulate adjuvants and indicates a mechanism of action 
more similar to a direct PRR ligand. However, based on some data (Wilson et 
al., 2012), it has been argued that Matrix-formulated saponin adjuvants 
probably do not signal through TLRs (Lövgren-Bengtsson et al., 2013; Morelli 
et al., 2012). 
Chemokine genes up-regulated by Matrix-M at the injection site included 
CCL2 that attract monocytes and DCs, and CXCL2 that recruit neutrophils 
(Charo & Ransohoff, 2006). This may in part explain the macroscopical and 
histological findings at the injection site after Matrix-M administration in pigs 
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(Paper II). CCL2 has been identified as an “adjuvant core response gene” in 
mice (Mosca et al., 2008) and was up-regulated in porcine skin after injection 
either with CpG, Emulsigen or polyphosphazene (Magiri et al., 2016). CCL2 
expression is thus likely to mirror adjuvant responses also in pigs. 
The cytokine genes IL10 and IL18 were up-regulated by Matrix-M at the 
injection site (Paper II). In the draining lymph node, IL1B was up-regulated, 
while IL18 was down-regulated. In blood, expression of IL1B and IL18 was 
affected by transport and mixing stress, but there was no differences in 
expression between pigs receiving Matrix-M or saline in advance (Paper IV). 
Caspase-1 is required for IL-1β and IL-18 release after inflammasome 
activation (Rathinam & Fitzgerald, 2016), and it is interesting that the CASP1 
gene was also up-regulated by Matrix-M at the injection site (Paper II). 
Furthermore, the inflammasome-associated receptor gene NLRP3 tended to be 
increased in blood from pigs receiving Matrix-M, compared to saline at 18 
hours post injection. The NLRP3 inflammasome may be activated in vitro by 
ISCOMATRIX (Wilson et al., 2014) as well as Matrix-M and the Quil-A 
saponin QS-21 (Marty-Roix et al., 2016). However, as NLRP3 is not 
constitutively expressed, pre-treatment with a TLR4-agonist or TNF-α was 
required for all three adjuvants. Up-regulation of genes for IL-1β, IL-18, 
caspase-1 and possibly also NLRP3 by Matrix-M can therefore indicate 
preparedness for inflammasome activation and IL-1β/IL-18 release in vivo. 
As combining particulate adjuvants with specific PRR agonists has been 
suggested recently for future vaccine designs (O'Hagan & Fox, 2015), the 
capacity of Matrix-M to modulate the expression of PRRs was evaluated. A 
number of PPR genes were up-regulated also at the injection site after 
Matrix-M administration, including TLR2, TLR4, the TLR-associated MYD88 
and PTX3, which encodes the soluble PRR pentraxin 3 (Fig. 2 in Paper II). In 
mouse muscle, pentraxin 3 was up-regulated both at gene level and as protein 
on muscle cells after injection with MF59 or CpG (Mosca et al., 2008). 
Pentraxin 3 is expressed on porcine bone marrow-derived DCs and increased in 
serum following influenza infection in pigs (Crisci et al., 2014). TLR2 was up-
regulated compared to saline in whole blood collected 18 hours after Matrix-M 
administration (Paper IV). At reanalysis of material from Paper II, up-
regulation of TLR2 in PBMCs collected 17 hours after Matrix-M 
administration was detected in three out of six pigs (Fig. 2). Both granulocytes 
and PBMCs from pigs express TLR2 (Alvarez et al., 2008), so the increase in 
TLR2 expression may have been confined to granulocytes that were not 
included in the analysis of PBMCs. In murine muscle, TLR2 was unaffected by 
the adjuvants alum, MF59, CpG, resiquimod and Pam3CSK4 (Caproni et al., 
2012; Mosca et al., 2008) but was significantly up-regulated by the TLR4 
 49 
agonist adjuvant glucopyranosyl lipid A (Lambert et al., 2012). TLR2 might be 
useful as a biomarker for Matrix-M stimulation, but surprisingly the TLR2 
expression was down-regulated by Matrix-M in all cell populations under in 
vitro conditions (Paper IV). 
Taken together, Matrix-M has a pronounced effect on expression of genes 
related to immune modulation both at the local injection site and in the 
draining lymph node. Although less pronounced, Matrix-M also induced 
measurable changes of the transcription in blood. The up-regulation of 
chemokine genes is presumably related to the influx of immune cells to the 
injection site and the draining lymph node and this transition of cells at various 
stages of activation might explain why early adjuvant effects also have been 
studied with some success in the blood (Pulendran et al., 2010). Matrix-M also 
modulate the expression of genes for PRRs and associated mediators (TLR2, 
TLR4, MyD88 and cytosolic RNA sensors) and inflammasome-associated 
genes (IL1B, IL18, CASP1). These results give an insight into possible 
mechanisms exerted by Matrix-M in priming the innate immunity of the host. 
 
 
Figure 2. Expression of TLR2 in PBMCs 
from porcine blood collected 17 hours after 
intramuscular injection with Matrix-M or 
saline. Expression was reanalysed with 
qPCR from archived material (Paper II) 
according to methods in Paper IV. The fold 
change was calculated against the expres-
sion in PBMCs 24 hours before injections. 
Individual fold change and geometric 
mean.
4.4 Profiling of interferon-related response after Matrix-M 
administration (Paper II, III, IV) 
Several of the most up-regulated genes in the response to Matrix-M at the 
injection site and in the draining lymph node were IRGs, which sparked the 
question if this was a true specific response or just a random effect due to the 
sheer number of IRGs in the genome. Gene set enrichment analysis of the 
transcriptional response to Matrix-M identified IRGs to be highly enriched (q < 
0.001) both at the injection site and in the draining lymph node (Paper II). 
IRGs constituted 38 out of 384 (10%) up-regulated genes at the injection site 
and 40 out of 92 (43%) up-regulated genes in the draining lymph node. The 
IRG response differed vastly between the tissues as only two IRGs were 
commonly up-regulated (Fig. 3 in Paper III) which was consistent with 
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previous reports on differences in gene expression between injection site and 
draining lymph node in response to adjuvants (Caproni et al., 2012; Lambert et 
al., 2012). Involvement of a type I IFN response was further corroborated by 
enrichment of a gene signature for pDCs (q < 0.05) at the injection site (Paper 
II). 
IFN genes present and annotated on the GeneChip array were IFNA2, 
IFNA6, IFNA8, IFNB1 (IFN-β) and IFNG (IFN-γ). For both tissues, none of 
these genes were differentially expressed and the expression of IFNB1 was 
below background. The transcription of IFNG tended to be up-regulated in the 
draining lymph node (FC = 4.5; q = 0.087). This lack of IFN gene induction 
could be due to the kinetics of the type I IFN response, as IFN genes are 
typically transiently expressed and then promote the subsequent induction of 
IRGs (Jenner & Young, 2005). It is also possible that IFN-α genes not present 
on the array were a part of the transcriptional type I IFN response. In a similar 
manner, injection of CpG in porcine skin down-regulated IFN-α gene 
expression at all time points for up to four days, concurrent with a high up-
regulation of several IRGs (Magiri et al., 2016). Nevertheless, gene expression 
analysis with qPCR for the draining lymph node revealed a prominent 
induction of IFN-β transcription in four out of six Matrix-M administered pigs 
(p < 0.05; Paper III) but revealed no regulation of IFN-α. The IRGs IRF7, MX1 
and OAS1 were up-regulated in the draining lymph node (Paper II). Screening 
using the qPCR plate array in blood indicated IRF7 as up-regulated 18 hours 
after Matrix-M injection, but none of the genes for IFN-α, IFN-β and IFN-γ 
nor the IRGs MX1 and OAS1 were affected (Paper IV). However, qPCR 
analysis on individual pigs presented a small but significant up-regulation of 
IFN-α (relative FC = 1.83; p < 0.05) in blood 18 hours after Matrix-M 
administration (Paper IV). 
A type I IFN response has not been described previously for ISCOM-
Matrix formulations. Such responses are typically associated with detection of 
nucleic acids, through TLRs, cytosolic RNA sensors or DNA sensing via the 
adaptor protein STING. However, a nucleic acid-independent induction of type 
I IFNs through STING by cell membrane fusion with liposomes or virosomes 
has been described (Holm et al., 2012). The saponins in ISCOM-Matrix 
engage cell membranes and may speculatively function in a similar way. The 
type I IFN-associated transcriptional response induced by Matrix-M included 
both IFN genes and IRGs, and could be detected both at the injection site, in 
the draining lymph node and in blood (Paper II, III, IV). IFN-α is known to 
increase CTL responses by promoting cross-presentation (Le Bon et al., 2003). 
Indeed, the levels of late T cell responses to vaccination in mice correlated 
with early expression in blood of the IRGs MYD88, STAT1 and DUSP5 
 51 
(Derian et al., 2016) and IRF7 was one of the key transcription factors up-
regulated in response to an effective human Yellow fever vaccine (Gaucher et 
al., 2008). All these IRGs were induced by Matrix-M in the draining lymph 
node, which may contribute to the CTL responses typically induced by Matrix-
formulated saponin adjuvants. 
4.5 In vitro exposure of blood cells to Matrix-M (Paper III, IV) 
Matrix-M promotes a prominent influx of neutrophils, induces a type I IFN-
related transcriptional response and a gene signature of pDCs at the injection 
site. In patients with systemic lupus erythematosus, autologous DNA in NETs 
from neutrophils is bound to autoantibodies and taken up by pDC via Fc-
receptor mediated endocytosis, thereby promoting IFN-α production (Garcia-
Romo et al., 2011; Lande et al., 2011). Porcine pDCs may also respond to self-
DNA in a similar fashion (Baumann et al., 2014). Thus, the capacity of 
Matrix-M to promote NET formation was evaluated. Stimulation with the 
positive control PMA induced NET formation in porcine polymorphonuclear 
leukocytes after four hours (Fig. 3 in Paper III). NETs were manifested as cells 
with condensed nucleus and genomic content released in fibre-like structures, 
as previously described for humans (Brinkmann et al., 2004) and pigs 
(Scapinello et al., 2011). In contrast, Matrix-M in concentrations from 0.3 to 3 
µg/ml did not induce NETs, not even after 16 hours stimulation time (Paper 
III). Yet, exposure to Matrix-M for 16 hours promoted both condensation of 
nuclei, disintegration of cells and formation of multiple DNA-containing 
fragments around the cells, indicative of pyroptosis (Labbé & Saleh, 2011). 
Pyroptosis was further supported by up-regulation of CASP1, IL1B and IL18 
by Matrix-M in vivo (Paper II) and the inflammasome activation reported for 
Matrix-M (Marty-Roix et al., 2016) and ISCOMATRIX (Wilson et al., 2014). 
In contrast, no apoptosis or necrosis was detected in PBMCs after 18 hours of 
in vitro exposure to Matrix-M, using equal concentrations as for the 
neutrophils (Paper III). 
The transcriptional response to Matrix-M was evaluated in vitro to 
distinguish influence of different cell types. A slight up-regulation of the gene 
for TNF-α was detected in PBMCs exposed to Matrix-M for six hours in vitro, 
(Paper III), but not genes for other cytokines readily induced by LPS or CpG 
(IFN-α, IFN-γ, IL-1β, IL-6, IL-10, IL-12p40, transforming growth factor 
[TGF]-β). PBMCs depleted of adherent cells, cultured for 16 hours and 
exposed to Matrix-M for 6 hours did not change their expression of any gene 
analysed (Paper IV). ISCOMATRIX induced barely any cytokines in murine 
macrophages and DCs generated in vitro (Wilson et al., 2012) and alum and 
 52 
MF59 did not induce any cytokine genes in splenocytes in vitro, in contrast to 
stimulation with Pam3CSK4, resiquimod and CpG (Caproni et al., 2012). 
However, both alum and MF59 up-regulated CXCL8, CCL4 and IL-1ra in 
human monocytes and monocyte-derived macrophages, but not in PBMCs or 
monocyte-depleted PBMCs (Seubert et al., 2008). The response to Matrix-M in 
monocytes following a 6-hour exposure included up-regulated genes for 
CXCL8 and for IL-1β after overnight culture (Paper IV). Both CXCL8 and 
IL-1β were increased in efferent lymph in sheep after ISCOMATRIX 
administration (Windon et al., 2000). Porcine lymphocytes cultured and 
exposed to Matrix-M for three days up-regulated genes for the pro-
inflammatory cytokines IL-1β and CXCL8 and the TH associated cytokines IL-
12p40, IL-17A and IFN-γ, while genes for the immunoregulatory cytokines IL-
10 and TGF-β were down-regulated (Paper IV). The same lymphocyte cultures 
exposed to Matrix-M only for the last six hours had a similar but less 
pronounced profile. Modulation of gene expression for IL-12p40, IFN-γ and 
IL-10 might explain the TH1-associated responses seen for Matrix-M vaccines 
(Pedersen et al., 2014; Magnusson et al., 2013; Madhun et al., 2009). In 
contrast, IL10 was up-regulated at the injection site 24 h after intramuscular 
administration (Paper II), possibly dampening the inflammation at that time. 
MoDCs exposed to Matrix-M for six hours did not change the expression of 
any cytokine gene analysed, except for a small increase in the expression of 
IFN-α. Presence of Matrix-M during the full 5-day generation of MoDCs 
however, promoted an increase in IFN-α expression and also induced 
substantial levels of IL-6 transcripts. Thus, a type I IFN response was indicated 
transcriptomically in vitro, as was detected both at the injection site, in the 
draining lymph node and in blood. However, expression of IFN-β, or the IRGs 
IFITM3, SPP1 and STING was not significantly affected in any of the cell 
cultures. 
Similar to other particulate adjuvants, Matrix-M induced little or no 
expression of cytokine genes when examined in vitro cell populations. 
Specifically, the in vitro system was not sufficient to reproduce the potent 
induction of type I IFN-related genes detected in vivo. DAMPs are released 
into the local tissue after injection with alum (Marichal et al., 2011) and MF59 
(Vono et al., 2013) that contribute to their adjuvant effect. The increased 
responses after prolonged exposure to Matrix-M likely caused release of 
DAMPs, which suggests involvement of DAMPs. Together with the fact that 
muscle cells may also be involved in the early immune response to adjuvant 
injection (Liang & Lore, 2016), simultaneous cultures of multiple cell types or 
ex vivo tissue explants could be more effective to study particulate adjuvants 
including Matrix-M. 
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4.6 Effects of Matrix-M in a contact exposure model (Paper IV) 
The immunomodulatory effects of Matrix-M suggest that it could be useful in 
emergency vaccines, where the aim is to delay infection by innate immune 
stimulation until adaptive responses appear (Foster et al., 2012). The induction 
of a type I IFN response by Matrix-M is especially interesting considering the 
antiviral effects, and IFN-α has previously been used with the aim to prevent 
PRRSV in pigs (Brockmeier et al., 2009). To investigate if Matrix-M could be 
used clinically to dampen infection, a contact exposure model was set up where 
SPF pigs were administered Matrix-M or saline and mixed with conventionally 
reared pigs (Paper IV). The pigs were also subjected to transport and mixing 
stress to provoke replication of for example PCV2 and/or H. parasuis that had 
been demonstrated in pigs from the SPF herd. The transport and mixing was 
followed by an increase in granulocyte counts and SAA levels for all SPF pigs, 
in accordance with earlier reports (Salamano et al., 2008; Pineiro et al., 2007; 
Dalin et al., 1993). Also the expression of IL1B, IL18, MYD88, NLRP3, TLR2 
and TLR4 was transiently increased in blood after transport and mixing but no 
effects of Matrix-M on these parameters were discerned. 
All SPF pigs mixed with conventional pigs developed respiratory disease in 
the contact exposure model (Paper IV), which was confirmed in seven out of 
eight pigs at necropsy. The conventional pigs remained healthy throughout the 
study, but lung lesions recorded at necropsy for these pigs revealed evidences 
for respiratory diseases. No signs of respiratory disease were recorded in any of 
the SPF pigs that were mixed with other SPF pigs (control), or in any SPF pig 
before the contact exposure. Two pigs in the group receiving saline displayed 
decreased general condition during the study and became lame, confirmed by 
joint lesions at necropsy. These symptoms were consistent with Glässer’s 
disease induced by H. parasuis infection (Oliveira & Pijoan, 2004), but H. 
parasuis was not demonstrated at necropsy. These two pigs had increased 
levels of granulocyte counts and SAA levels throughout the experiment, and 
SAA levels are known to correlate well with clinical symptoms and disease 
severity (Sjolund et al., 2011; Cray et al., 2009; Hulten et al., 2003). Similarly, 
these pigs had increased gene expression of IL18 and TLR2 throughout the 
experiment, in contrast to the other pigs. No signs of systemic disease were 
detected clinically or at necropsy in any other SPF pig, including all four pigs 
that received Matrix-M.  
All blood parameters measured declined to baseline after the initial 
transport and mixing stress response in the pigs administered Matrix-M. 
However, in three out of these four pigs, there was an increase in granulocyte 
counts, SAA levels and gene expression for IL1B, IL18, MYD88, TLR2 and 
TLR4 on day 5 or 6. Despite lack of clinical symptoms, it is likely that this 
 54 
reflected the beginning of systemic disease also in the Matrix-M pigs. A 
similar kinetic was seen for pigs in a contact exposure experiment with PRRSV 
(Li et al., 2013), where vaccination alleviated and delayed symptoms for up to 
five days after inoculation with PRRSV in contact pigs on the same day, 
compared to unvaccinated controls. Similarly, Matrix-M may have delayed or 
diminished systemic disease development at contact exposure (Paper IV). 
The contact exposure model simulated mixing of pigs with various health 
statuses, mimicking field conditions at allocation of grower pigs, and 
successfully provoked respiratory disease in all exposed SPF pigs. Symptoms 
that resembled Glässer’s disease, and correlated with SAA levels, granulocyte 
counts and the expression of several genes analysed, were only detected in two 
SPF pigs receiving saline and not in pigs given Matrix-M. Despite the limited 
number of animals, this indicated that Matrix-M modulated the disease kinetic 
in pigs following transport, mixing and exposure to new pathogens. 
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5 Conclusions 
From results in this thesis it can be concluded that: 
Ø The Affymetrix GeneChip Porcine Genome Array can be successfully used 
to study responses to various immunological stimuli in porcine tissues. 
Ø Matrix-M is well tolerated by pigs. It promotes a mild local inflammation 
both at the injection site and in the draining lymph node, causing a 
redistribution of immune cells as evidenced by an altered expression of 
genes encoding chemokines and chemokine receptors. 
Ø Matrix-M affects gene expression of cytokines, pattern recognition 
receptors and associated proteins and thereby primes cells for further 
immune regulation. 
Ø Based on circumstantial evidence, Matrix-M induces a type I interferon 
response in pigs. 
Ø In vitro responses to Matrix-M differ from those in vivo and show a 
considerable variation depending on cell type and culture condition. 
Ø A contact exposure model in pigs was successfully established to reproduce 
respiratory disease in grower SPF pigs. 
Ø Based on a limited number of pigs, administration of Matrix-M in the 
contact exposure model could delay the onset of systemic disease. 
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6 Future perspectives 
The gene expression profiling provided valuable information on the response 
to Matrix-M in vivo not readily detected using traditional methods. Microarray 
or RNA-Seq technology can be used in the pig to illuminate differences 
between various Matrix formulations and/or saponin-based adjuvants. As 
combinations of Matrix formulations and immunomodulatory molecules have 
been used with success in murine vaccines, the early gene signatures of such 
combinations are also worth exploring. Characterization of the early response 
to Matrix formulations or other adjuvants together with antigen can help 
finding correlates with long-term immunity in a systems biology approach. 
With the possibility of porcine infection models, gene expression profiling 
should enable the finding of innate immune signatures for adjuvants correlating 
with protection, highly sought for in vaccine development research. 
Whole tissue or blood gene expression profiling provide limited 
information on the cellular origin of the response. Phenotypic characterization 
of the cells involved in the early response to saponin-based adjuvants such as 
Matrix-M would help understanding their mode of action. Archived material 
preserved in liquid nitrogen or as formalin-fixed, paraffin-embedded tissues are 
available for such studies. 
The interferon response induced by Matrix-M is puzzling as no available 
model fully explains it. Merging of cell membranes can induce interferon in the 
lack of nucleic acid or other direct PRR ligands, but do not explain the weak 
type I interferon responses detected in vitro. ISCOM-Matrix can promote 
escape of antigen to the cytosol that may also occur for DAMPs present or 
released at injection. Novel in vitro systems should therefore include defined 
DAMP molecules (nucleic acid, heat-shock proteins, free ATP, etc.) when 
exposing cells to Matrix formulations. To imitate the in vivo situation, less 
defined sources of DAMPs may be attained by using tissue explants or co-
cultures of tissue cells and immune cells. 
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The results presented for Matrix-M suggests using it clinically as an 
immunomodulator or in emergency vaccines to combat infection by means of 
innate immune activation. In addition to periods of stress, such as transport and 
mixing of groups with different health statuses, there are porcine diseases for 
which there are few or no effective vaccines available. Field studies using 
Matrix formulations clinically as immunomodulators or in emergency vaccines 
are therefore motivated. 
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7 Populärvetenskaplig sammanfattning 
Vaccinering är ett av de bästa sätten att skydda en värd mot infektion, genom 
att skapa långvarig immunitet mot en patogen (sjukdomsalstrande mikro-
organism). Ett vaccin består av en patogen-specifik del som immunförsvaret 
känner igen och bildar skydd emot, samt en immunstimulerande del som drar 
igång immunsvaret. De immunstimulerande delarna består av varningssignaler 
som kan vara kroppsfrämmande, ofta ämnen från patogener, eller kroppsegna 
signalämnen från skadade eller döda celler. Varningssignaler känns igen av 
kroppens immunceller genom speciella varningssignalreceptorer. Traditionella 
vaccin av döda eller försvagade patogener innehåller naturliga varnings-
signaler, men moderna vaccin kräver ofta hjälp av så kallade adjuvans som 
verkar genom att aktivera dessa varningssignalreceptorer. Eftersom adjuvans 
aktiverar immunreaktioner kan de även användas för att tillfälligt bekämpa en 
infektion, vilket finns ett behov av inom modern djurproduktion. 
En typ av adjuvans är framrenade saponiner ur barken från såpträdet 
(Quillaja saponaria). Om man blandar Quillaja-saponiner med ämnen 
liknande de som finns i cellmembran så bildas en sorts nanopartiklar. 
Matrix-M är ett sådant adjuvans som för närvarande undersöks i kliniska 
studier för humana vaccin, men liknande adjuvans har under lång tid använts i 
veterinära vaccin. Hur dessa adjuvans fungerar är till stor del fortfarande okänt, 
vilket skapar svårigheter om man vill förbättra dem på ett förutsägbart sätt. 
Denna avhandling har undersökt de tidiga immunreaktionerna mot Matrix-M 
hos grisar, både i det levande djuret och i blodceller samlade från grisar och 
stimulerade på labb. Studierna på Matrix-M gjordes utan patogen-specifika 
vaccindelar för att undersöka den särskilda effekten av adjuvanset. 
När kroppen reagerar på ett immunologiskt stimuli, oavsett om det är en 
patogen eller ett adjuvans, så förändras uttrycket av ett stort antal gener. Med 
så kallad microarray-teknik kan man mäta uttrycket av samtliga gener som 
finns hos en individ, för däggdjur ungefär 20 000 stycken. Med hjälp av 
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datorbaserade analyser kan man skapa en profil utifrån vilken typ av stimuli 
som påverkat individen. I början av detta arbete upprättades en metod för att 
använda microarray för att mäta immunreaktioner i grisvävnad genom att 
undersöka arkiverat material från virusinfekterade tarmar.  
Injektion med Matrix-M i grisar orsakade ett tydligt inflöde av immunceller 
till den injicerade muskeln, men även till den närliggande lymfknutan. Detta är 
intressant eftersom det framför allt är i lymfknutan det långvariga immunsvaret 
bildas. Microarray-analyserna påvisade ökat genuttryck för så kallade 
cytokiner och kemokiner i båda dessa vävnader, proteiner som rekryterar och 
aktiverar immunceller. Även gener för varningssignalreceptorer ökade sitt 
utryck, vilket tillsammans tyder på att Matrix-M kan skapa en aktiv 
immunologisk miljö efter injektion som troligen är gynnsam vid vaccinering. 
Genuttrycket för en av dessa varningssignalreceptorer (TLR2) var även förhöjt 
i blod, och denna skulle kunna användas som biomarkör för den tidiga effekten 
av adjuvans. Matrix-M aktiverade även gener för så kallade interferoner och 
interferon-relaterade gener, signalämnen aktiva mot virusinfektion men som 
vid vaccination även främjar ett långvarigt skydd mot framför allt virus. 
Interferon-svaret kunde detekteras både i vävnad och blod från injicerade 
grisar, och i viss mån i blodceller som odlats på labb. Generellt var dock 
immunreaktionerna mot Matrix-M i odlade blodceller svaga i förhållande till 
vad som sågs i den levande grisen. Mer arbete krävs för att hitta bra system där 
man på labb kan undersöka effekten av denna typ av adjuvans. 
Den immunstimulerande effekten av Matrix-M undersöktes till sist i en 
infektionsmodell. Smittfria grisar, som till stor del saknar skydd mot vanliga 
patogener som drabbar gris, behandlades med Matrix-M eller koksaltlösning 
(kontroll) innan de transporterades och blandades med konventionellt uppfödda 
grisar. Denna stress och utsatthet för ny smitta framkallade luftvägssjukdom i 
samtliga smittfria grisar. Några av de som inte fått Matrix-M visade dessutom 
tecken på transportsjuka, en infektionssjukdom som kan ge påverkat 
allmäntillstånd och ledproblem. Dessa symptom sågs samtidigt som 
förändringar i blodbilden och förhöjning av inflammations-markören SAA och 
genuttryck i blodet. Behandling med Matrix-M verkade alltså kunna hämma 
utvecklingen av dessa symptom. 
Sammantaget visade detta projekt att microarray är en fungerande metod för 
att utvärdera adjuvans. Matrix-M aktiverar en tydlig immunreaktion i grisar 
som troligen är gynnsam när man inkluderar Matrix-M i vaccin. 
Immunreaktionerna orsakade av Matrix-M skulle även kunna användas som 
förebyggande behandling i djurhållning vid skeden då det finns risk för 
infektion framkallad av stress, som transporter eller när man blandar djur från 
olika grupper. 
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